Next Article in Journal
Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21
Next Article in Special Issue
Effects of Monovalent Salt on Protein-Protein Interactions of Dilute and Concentrated Monoclonal Antibody Formulations
Previous Article in Journal
Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies
Previous Article in Special Issue
Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibodies
Volume 11
Issue 1
10.3390/antib11010018
antibodies-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients

by
Mepur H. Ravindranath
1,2,*,
Narendranath M. Ravindranath
3,
Fatiha El Hilali
4,
Senthamil R. Selvan
5 and
Edward J. Filippone
6
1
Department of Hematology and Oncology, Children’s Hospital, Los Angeles, CA 90027, USA
2
Emeritus Research Scientist at Terasaki Foundation Laboratory, Santa Monica, CA 90064, USA
3
Norris Dental Science Center, Herman Vostro School of Dentistry, University of Southern California, Los Angeles, CA 90089, USA
4
Faculty of Medicine and Pharmacy of Laayoune, Ibn Zohr University, Agadir 70000, Morocco
5
Tetracore Inc., Rockville, MD 20850, USA
6
Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19145, USA
*
Author to whom correspondence should be addressed.
Antibodies 2022, 11(1), 18; https://doi.org/10.3390/antib11010018
Submission received: 20 December 2021 / Revised: 7 February 2022 / Accepted: 22 February 2022 / Published: 2 March 2022
(This article belongs to the Special Issue Monoclonal Antibody-Directed Therapy Series II)
Browse Figures
Versions Notes

Abstract

:
Serum anti-HLA-I IgG are present in non-alloimmunized males, cancer patients, and transplant recipients. Anti-HLA-I antibodies are also present in intravenous immunoglobulin (IVIg), prepared from the plasma of thousands of healthy donors. However, the HLA-Ia reactivity of IVIg diminishes markedly after passing through HLA-E HC-affinity columns, suggesting that the HLA-I reactivity is due to antibodies formed against HLA-E. Hence, we examined whether anti-HLA-E antibodies can react to HLA-I alleles. Monoclonal IgG antibodies (mAbs) against HCs of two HLA-E alleles were generated in Balb/C mice. The antibodies were analyzed using multiplex bead assays on a Luminex platform for HLA-I reactivity. Beads coated with an array of HLA heterodimers admixed with HCs (LABScreen) were used to examine the binding of IgG to different HLA-Ia (31-HLA-A, 50-HLA-B, and 16-HLA-C) and Ib (2-HLA-E, one each of HLA-F and HLA-G) alleles. A striking diversity in the HLA-Ia and/or HLA-Ib reactivity of mAbs was observed. The number of the mAbs reactive to (1) only HLA-E (n = 25); (2) all HLA-Ib isomers (n = 8); (3) HLA-E and HLA-B (n = 5); (4) HLA-E, HLA-B, and HLA-C (n = 30); (5) HLA-E, HLA-A*1101, HLA-B, and HLA-C (n = 83); (6) HLA-E, HLA-A, HLA-B, and HLA-C (n = 54); and (7) HLA-Ib and HLA-Ia (n = 8), in addition to four other minor groups. Monospecificity and polyreactivity were corroborated by HLA-E monospecific and HLA-I shared sequences. The diverse HLA-I reactivity of the mAbs are compared with the pattern of HLA-I reactivity of serum-IgG in non-alloimmunized males, cancer patients, and ESKD patients. The findings unravel the diagnostic potential of the HLA-E monospecific-mAbs and immunomodulatory potentials of IVIg highly mimicking HLA-I polyreactive-mAbs.

1. Introduction

HLA class-I expressed on human cell surfaces are heterodimers formed by the non-covalent association of a polymorphic, glycosylated 42-kDa heavy chain (HC) with β2-microglobulin (β2m), a 12-kDa light chain. The HC consists of three helical structures, α1, α2, and α3. HLA-I molecules are polymorphic consisting of several alleles of classical HLA-Ia (HLA-A 6921 alleles, HLA-B 8181 alleles, and HLA-C 6779 alleles) and non-classical HLA-Ib (HLA-E 271 alleles, HLA-F 45 alleles, and HLA-G 88 alleles).
Primarily, intact HLA-I molecules bind to peptides that are derived from proteolytic degradation of cytoplasmic proteins, viruses, and pathogens. The peptide carried in the groove of α1 and α2 domain of the HC interacts with the T cell receptor, and culminates in activation, proliferation, and differentiation of the CD8+ T cells that kill cells that present the specific peptide antigen [1]. After presenting or losing the peptide, HC dissociates from β2m and is released by membrane matrix metalloproteinases (MMPs) [2] from the cell surface into the microenvironment and subsequently the circulation, where it undergoes proteolysis. The HC shedding determines the half-life of HLA-I, which may vary with cells, depending on glycosylation and sialylation [3]. The intact HLA-I molecules are identified with the monoclonal antibody (mAb) W6/32 that recognizes an epitope on β2m (residues 3 and 89) and on the HC residue 121 of all isoforms of HLA-I molecules [4].
In addition, cell surface monomeric (β2m-free HCs) HLA-I variants have been recognized since the 1980s. The HC monomers are found on cells activated by inflammation, infection, trauma, malignancy, cytokines, and chemokines [5,6,7,8,9,10,11,12,13,14,15]. Various functional interactions of these HLA-I monomers have been periodically reviewed [15,16,17,18,19]. The monomeric HLA-I HC functions as a ligand to killer-cell immunoglobulin-like receptors, KIRs (KIE3DS1) on human NK cells and regulates their function [18,19]. These monomers are recognized by the mouse mAb HC-10 but not by mAb W6/32. The epitope of HC-10 is identified between amino acid positions 57 and 62 of the HLA α1 HC; arginine at position 62 (R62) is crucial for recognition [20]. After the shedding of HCs, the amino acid sequences that were masked by β2m are exposed.
The exposure of such cryptic sequences and their fragments is known to elicit an antibody response [21,22,23]. Therefore, one can expect antibodies directed against the HCs of various HLA-I isoforms in normal and healthy individuals. Indeed, natural HLA-Ia Abs occur in normal and healthy human sera and particularly in non-alloimmunized males [24,25,26,27,28,29,30], and they are anticipated to be restricted to native alleles. However, the results of antibody analysis revealed that the antibodies were reactive against several allo-HLA molecules [29,30]. The antibody reactivity of the sera was carried out with LABScreen single antigen bead (SAB) assays using LABScreen beadsets. Examination of the SABs with the mAb W6/32, specific for β2m associated HCs, and the mAb HC-10, confirmed the admixture of HLA-I monomeric HC variants with the intact HLA-I alleles in these beadsets [30,31]. In this context, the primary objective is to understand and elucidate the origin of the allo-HLA reactive Abs occurring in healthy individuals as well as in cancer and transplant patients.
Previously, we have observed that anti-HLA-E mAbs (MEM-E/02, MEM-E/06, MEM-E/07, MEM-E08, and 3D12) not only bind to HLA-E but also to other HLA-I isoforms [32,33], such as the “natural HLA antibodies” observed in the sera of healthy non-alloimmunized males. An inhibition assay with peptides located in the HC, masked by β2m in intact HLA but exposed in β2m-free HCs, was designed to further ascertain the affinity of the mAbs to HLA-E and other HLA-I isoforms. Strikingly, these peptides not only inhibited the mAb binding to HLA-E but also to other HLA-I isomers, namely HLA-A, HLA-B, and HLA-C. These observations suggest that the antibodies reactive to several alleles in normal healthy individuals as well as in those patients waiting for organ transplantation could be those formed against the monomeric variants of HLA found on activated immune cells. If this is true, why are Abs formed against some, but not all, HLA-I alleles of all isomers, although all of them share same sequences such as AYDGKDY?
To address these issues, we have generated monoclonal antibodies to the two recombinant (deglycosylated) heavy chains of HLA-E (HLA-E*01:01 and HLA-E*01:03), which differ in the amino acid at position 107 (HLA-ER107 and HLA-EG107). Here, we study their reactivity against β2m-free HCs of all HLA-Ia alleles. In doing so, we unravel the striking diversity in the mAbs’ specificity, possibly due to differences in the antigenicity and/or immunogenicity of such epitopes.

2. Material and Methods

2.1. Production of Murine Monoclonal Antibodies against HCs of HLA-ER107 and HLA-EG107

Murine monoclonal antibodies were produced following the guidelines approved by the National Research Council’s Committee on Methods of Producing Monoclonal Antibodies [34]. The recombinant polypeptide HCs of HLA-E*01:01 (HLA-ER107) and HLA-E*01:03 (HLA-EG107) (10 mg/mL in 2-(N-morpholino) ethanesulfonic acid (MES) buffer) were obtained from the Immune Monitoring Laboratory, Fred Hutchinson Cancer Research Center (University of Washington, Seattle, WA, USA). Fifty micrograms of the antigen were diluted in 100 μL of PBS (pH 7.4) and were mixed with 100 μL of the adjuvant TiterMax (Sigma–Aldrich, St Louis, MO, USA) before injection into the footpad and peritoneum of mice. Each antigen was injected to 2 mice. Three immunizations were given at about 12-day intervals, with an additional immunization after 12 days for mice receiving HLA-EG107. Only 1 fusion of specific antibody-producing B cells with myeloma tumor cells was carried out for HLA EG107. The clones were cultured in a medium containing RPMI 1640 w/L-glutamine and sodium bicarbonate (Sigma–Aldrich, St. Louis, MO, USA, Cat. No. R8758), 15% fetal calf serum, 0.29 mg/mL L-glutamine/Penn-Strept (Gemini-Bio, MedSupply Partners, Atlanta, GA, USA; Cat. No. 400-110), and 1mM sodium pyruvate (Sigma; Cat. No. S8636). Several clones were also grown using Hybridoma Fusion and Cloning Supplement (HFCS; Roche Applied Science, Indianapolis, IN, USA; Cat. No. 11363735001). Isotypes of all the mAbs were characterized, and no IgM Abs were detected.
Almost all the clones were cryopreserved in liquid nitrogen at the Terasaki Research Institute. The hybridomas of monospecific mAbs (TFL-033, TFL-034, TFL-073, TFL-074, and TFL-0145) and polyreactive mAbs (TFL-006 and TFL-007) were patented [35,36], and deposited with American Type Culture Collection, Patent Depository, 10801, University Blvd. (Manassas, VA, USA).

2.2. Single Antigen Beads Assay with Single-HLA Antigen-Coated Microbeads

To monitor IgG reactivity to HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G, the culture supernatants as well as human sera, were analyzed with SAB assay using dual-laser flow cytometry on a Luminex platform (Luminex xMAP multiplex technology), as described elsewhere [37]. The beadset consists of a panel of color-coded beads on which individual HLA antigens have been covalently bound (xMap assays) to identify antibody specificities. The LABScreen xMap microbeads contain two reporter fluorophores that are proportionally varied to identify them as one of 100 possible bead identifiers. The array of HLA antigens representing various alleles on the beads are listed on the One Lambda web site (www.onelambda.com (accessed on 4 November 2011)) under Ab-detection products/LABScreen Single Ag Product sheet/HLA-Ia combi-LS1A04-Lot 002 or LS1A04-Lot 005 Worksheet Rev-1. The single recombinant HLA-Ia antigens in LS1A04-lot 007 were used for screening the mAbs. The SAB products in every lot include 31 HLA-A, 50 HLA-B, and 16 HLA-C alleles. The beads supplied by the manufacturer have 2 categories of proteins attached to the beads [32,33,37,38,39]: (1) HLA HC polypeptide only and (2) HC in association with β2m. The mean fluorescent intensity (MFI) values were obtained for IgG antibodies reacting to HLA-coated beads each allele of every HLA isomer. The MFI values were corrected against those obtained with negative control values for each allele.
The recombinant HLA-E, HLA-F, and HLA-G HCs (10 mg/mL in MES buffer) were obtained from the Immune Monitoring Laboratory, Fred Hutchinson Cancer Research Center (University of Washington, Seattle, WA, USA) and were coated specially onto beads by the manufacturers (One Lamda Inc., Los Angeles, CA, USA.) of LABScreen beadset. The HLA-E HCs used for immunization were utilized for coating the beads. The recombinant HLA-E, HLA-F, and HLA-G HCs were individually attached by a process of simple chemical coupling to 5.6-micron polystyrene microspheres, which were internally dyed with infrared fluorophores. Positive beads were coated with murine IgG and negative beads were coated with serum albumin (HSA/BSA). In addition, beads treated with PBS were also used as another negative control. For HLA-E, HLA-F, and HLA-G, the control beads (both positive and negative) were added separately. The culture supernatants were diluted 1:50 in PBS at pH 7.2 and 20-μL were added to the 2-μL of antigen-coated microbeads (at 10 to 1 ratio). Secondary fluorescence-labeled anti-mouse polyclonal Abs were diluted 1/100 (anti-mouse IgG (H + L), Cat. No. 115-116-146, protein concentration at 0.5 mg/mL; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). For identifying the isotypes, anti-Fc secondary mouse anti-isotype Abs (human-absorbed anti-mouse IgG1 (Cat. No. 1070-095) obtained from Southern Biotech, Birmingham, AL, USA) were used at concentration 0.5 mg/mL, after 1:100 dilution.
The reporter fluorophore intensity was measured by a Luminex flow cytometer together with the microbead identifiers, and the fluorescence measurement was classified by bead identifier. The trimmed mean was obtained by trimming a percentage off the high and low ends of a distribution and finding the mean of the remaining distribution. The HLA-Ia microbeads have built-in control beads: positive beads that were coated with murine IgG and negative beads that were coated with serum albumin (HSA/BSA). For HLA-E, HLA-F, and HLA-G, the control beads (both positive and negative) were added separately.
Normalized MFI of mAbs were obtained as follows: ((Trimmed MFI—MFI of mAbs treated with PBS alone)—(negative control beads)). This is an essential step because when antibodies were tested on beads with PBS alone, differential MFI values were observed with different HLA molecules [37,38,39]. Each analysis included data obtained from >100 beads and was performed in duplicate. The MFI cut off used for positive HLA reactivity was 500.

2.3. Anti-HLA IgG Purified from the Sera of Non-Alloimmunized Males

The sera used were from non-alloimmunized male volunteers from the Terasaki Foundation Laboratory (TFL). Five milliliters of blood was collected from each volunteer after obtaining informed consent. Fresh sera were used for purification. However, the sera and purified IgG were also frozen and stored at the TFL. The sera were not treated with EDTA. First the sera were tested directly on the SAB assay. To further ascertain the presence of IgG reacting to HLA antigens, IgG was purified from sera using protein-G columns obtained from ThermoFisher Scientific (Rockford, IL, USA). The recombinant protein-G contains two Fc-binding domains and is devoid of albumin and cell surface-binding sites. This was coupled to beaded agarose and ultra-link affinity resins. Protein-G agarose resin binds to all human IgG subclasses but not to IgM, IgD, IgA, or serum albumin. The serum (132 μL) was applied to the protein-G agarose resin after washing the resin twice with PBS, pH 7.2. The serum was mixed well, incubated for 10 min and was passed through the resin. The resin was washed three times with wash buffer (PBS, pH 7.2). The agarose-bound IgG was eluted in three vials using acidic buffer (pH 2.8; 400 μL) and immediately recovered in alkaline buffer (pH 8.5) under centrifugation for a minute, to neutralize the eluates. Either soluble antigen or any other serum factor, such as polypeptides or peptides bound to IgG, would have dissociated at the acid pH used for elution. Three eluates (each 400 μL) were collected and the concentrations of the fractions were determined using the calculations provided in the manual of Eppendorf BioPhotometer (Copyright by 1998 by Eppendorf Netheler—Hinz GmbH, Hamburg, page 87). The calculation of the protein-G fractions was carried out using the calculated factor: C = absorbance at A280—absorbance at A260 to obtain the concentration of the protein (mg/mL). The protein-G eluates (E1, E2, and E3) were tested neat; however, during protein-G elution, the IgGs were diluted 1/10. For this report, we have restricted our observations to data obtained from eluate-2, because the MFIs of E2 were consistently higher than the MFIs of E1 and E3. To detect IgG reactivity to HLA-I alleles in protein G column purified E2 of non-immunized male sera, a multiplex Luminex-based SAB assay was used. The recombinant HLA-Ia antigens in LABScreen beads (1A04-Lot 007) were used for screening. Normalized MFIs of human sera were obtained as follows: ((Trimmed mean MFI—MFI of mAbs treated with PBS alone)—(Negative control bead MFI)—(Negative sera MFI)).

2.4. Sera Anti-HLA IgG Antibodies in Melanoma Patients before and after Autologous Vaccine

In this study, we have used sera collected from patients who participated in the clinical trial, NCI-V01-1646, at the Hoag Cancer Center, Newport Beach, CA, USA. The sera and tumor cells were obtained after institutional review board approval and patient consent [40]. The preparation of the autologous vaccine was described in detail elsewhere [40]. Essentially, tumor cell lines were established from the respective biopsies, expanded (to 150 × 106 cells), and treated with IFNγ for 3 days with (1000 U/mL; ACTIMMUNE, InterMune, Brisbane, CA, USA). The treated cells were harvested, irradiated (at 100 Gray) to arrest growth, and cryopreserved until pulsing with autologous dendritic cells (DCs). For final preparation of the vaccine, tumor cells (TCs) obtained from each patient were incubated (overnight at 37 °C) with autologous DCs at a ratio of 1:1 and cryopreserved into aliquots. Just prior to each vaccination, aliquots of DCs loaded with tumor cells were thawed at 37 °C, washed (2× with AIM-V), mixed with GM-CSF (500 μg/mL) with an average TCs-DCs dose of 1.6 × 107 [±0.8 × 107] cells with 78% viability, and were administered to patients subcutaneously. TCs pulsed with DCs, were given weekly for 3 weeks, then monthly for 5 months. Sera were collected on weeks 0 (before immunization), 4, and 24 (after immunization). This study was restricted to six vaccine recipients whose cell lines showed positivity for anti-HLA-E mAb MEM-E/02 (1/1000). The patient characteristics and HLA reactivity of the sera (diluted 1/10) were described elsewhere [41]. To detect the presence of Abs in the sera that react to HLA-E and HLA-Ia alleles, multiplex Luminex®-based immunoassay (One Lambda, Canoga Park, CA, USA) was used, as described above.

2.5. Sera Anti-HLA IgG Antibodies in HLA-Sensitized End-Stage Kidney Disease Patients Waiting for Transplantation

HLA-I reactivity of the sera of 8 HLA-sensitized end-stage kidney disease (ESKD) patients waiting for donor organs was examined (7 females and 1 male). The causes of ESKD among these patients included diabetes mellitus (DM), hypertensive nephrosclerosis (HN), and lupus erythematosus (LE). Three patients (10DMF73, 12DMF49, and 20HNF64) were possibly sensitized by pregnancy, three (1DMM64, 11DMFDM, and 19HNF45) by transfusion, one (17LEF24) due to prior transplantation, and one (5DM) for unknown reasons. 1DMM64 was transplanted within a year after sample collection for this study. Sera were randomly selected from the Downstate pre-transplant clinic at Sunny Downstate Health Sciences University, University Hospital of Brooklyn (UHB), New York by Prof. Dr. Allen Norin and Dr. Ballabh Das. SAB/DSA study protocols were reviewed and approved by the Downstate Institutional Review Board (IRB), (IRB No. 1232938-3 and No. 341403-1). Sera were examined with LABScreen SABs (Cat. No. 1A04, Lot No. 10). All assays were carried out simultaneously on a single day by one HLA technologist at Terasaki Foundation Laboratory (TFL). For these assays, serum (20 µL) was diluted (1/10) and then incubated with 2 μL of beads for 30 min at room temperature on a shaker. The beads were then washed (3×) with wash buffer. The HLA antigen-IgG binding was assessed with a PE-conjugated secondary-Ab, goat anti—IgH PolyFab (One Lambda Inc., Canoga Park, CA, USA, Cat. No.A82) by incubating the detection-Ab (50 μL at 5 μg/mL) for 30 min at room temperature on a shaker. After washing, the beads were suspended in 1× PBS before acquisition on the Luminex® platform. At least 100 beads were counted for each antigen. The assay includes positive control (coated with human IgG) and negative control (no antigen) beads. We recorded MFI after normalizing the Trimmed mean MFI.

3. Results

Heavy chains (HCs) of two different alleles of HLA-E, which differ in their amino acid residue at position 107, were used for immunization. In one allele (HLA-E*01:01, HLA-ER107), arginine (R) was found in position 107 and in another (HLA-E*01:03, HLA-EG107), arginine was replaced by glycine (G). The monoclonal antibodies generated from these two different alleles were separated as group-R and group-G. Although HCs of each allele were immunized into two mice, only one fusion was carried out for HLA-EG. Therefore, the number of mAbs were higher in HLA-ER than in HLA-EG.

3.1. Classification of Monoclonal Antibodies Formed against HLA-E*01:01 (HLA-ER) and HLA-E*01:03 (HLA-EG)

Table 1 shows the diverse groups (R-I to R-X and GI to GX) and the number of mAbs developed by immunizing HCs of HLA-ER and HLA-EG, and it demonstrates the reactions to different HLA-Ia and HLA-Ib alleles. All mAbs listed in the tables were positive to HLA-E but showed differential reactivity to other alleles, namely 31 HLA-A, 50 HLA-B, 16 HLA-C, and 1 each of HLA-F and HLA-G alleles.
Groups R-I (n = 20) and G-I (n = 5) are unique in that they are HLA-E monospecific mAbs. They do not recognize (all MFIs <400) any alleles of other HLA-Ia or HLA-Ib alleles.
Groups R-II (n = 1) and G-II (n = 7) are mAbs specific for HLA-Ib, in that they recognize alleles of HLA-E, HLA-F, and HLA-G but not any of the HLA-Ia alleles.
Group R-III (n = 1) is another unique category of HLA-E mAb that recognizes only B*4006 but not any other HLA-Ib or HLA-Ia alleles.
Group R-VI (n = 29) and G-VII (n = 25) are HLA-E mAbs, that do not recognize any other HLA-Ib loci, such as HLA-F or HLA-G, but recognize all HLA-Ia loci (HLA-A, HLA-B, and HLA-C).
A major category of HLA-E mAbs are those that do not recognize any other HLA-Ib loci but recognize HLA-B, and HLA-C and the A*1101 allele (among all HLA-A alleles) in both R and G groups (R-V: n = 68 and G-VI: n = 15).
The most interesting R and G groups are those anti-HLA-E mAbs that bind to all other HLA-I loci, namely HLA-A, HLA-B, HLA-C, HLA-F, and HLA-G (R-X: n = 2 and G-X: n = 4). These are indeed considered as truly HLA-I polyreactive antibodies.
In addition to these antibodies, there are other groups of HLA-E mAbs that bind to different loci in R and G groups. Furthermore, there was one mAb that tested negative for HLA-E but positive only for A*1101 (unpublished).

3.2. The Monospecific mAbs Formed against HLA-E*01:01 and HLA-E*01:03

Table 2 illustrates 20 HLA-E monospecific mAbs developed after immunizing two different Balb/c mice with recombinant HLA-ER107 and 5 HLA-E monospecific mAbs after immunizing with recombinant HLA-EG107. Isotypes of these mAbs were IgG1 in 20/25 mAbs and IgG2a in 3 mAbs out of 25. Isotypes of the two mAbs could not be tested. The MFIs ranged from 10K to 22K for 13 of 25 mAbs. To determine the possible binding sites of these monospecific mAbs, we compared the amino acid sequences of the two HLA-E allelic sequences with the amino acid sequences of 504 HLA-A, 844 HLA-B, and 283 HLA-C alleles. The amino acid sequences of HLA-E, HLA-F, and HLA-G are compared in Figure 1. The HLA-E specific sequences in the α1 and α2 helical domains are shown within the red boxes. Figure 2 provides additional proof for HLA-E monospecificity obtained by comparing the profiles of the amino acid sequences of 30 alleles of HLA-A, 58 alleles of HLA-B, and 15 alleles of HLA-C coated on the microbeads of LABScreen beadsets.
To further confirm the monospecificity, we carried out dosimetric inhibition of purified culture supernatants of TFL-033 with two HLA-E-restricted peptides, 65RSARDTA71 and 143SEQKSNDASE152, at concentrations ranging from 4.4 to 0.27 mg/well. Although both peptides showed inhibition, the α2 helical peptide SEQKSNDASE showed better dosimetric inhibition than the other peptide [37]. Figure 3 illustrates the conformational orientation of the HLA-E mAb specific epitopes on the α1 and α2 helices of HLA-E. It is important to note that the mAbs do not recognize linear epitopes but recognize conformationally altered epitopes. The yellow letters in the figures represent the exposed amino acids on the epitope, while the amino acids in the white letters represent the masked ones.
Indeed, this is an important characteristic feature of monoclonal antibodies recognizing quaternary structures. The specific amino acids at the center of an epitope that are recognized by an antibody are designated as eplets, and usually consist of one to several amino acids. Another noteworthy finding of the HLA-E sequences is that there are several HLA-E specific sequences in addition to 65RSARDTA71 and 143SEQKSNDASE152, as shown in red boxes in Figure 1. These sequences may serve as the epitopes for other HLA-E monospecific mAbs.

3.3. The HLA-Ib Specific but HLA-Ia Non-Reactive mAbs

Table 3 documents ten HLA-Ib reactive mAbs that are totally non-reactive to HLA-Ia, of which one (TFL-050) was produced by HLA-ER (Group R-II) and the other nine mAbs were produced by HLA-EG. Seven of the nine mAbs were binding to HLA-E, HLA-F and HLA-G (Group G-II). Interestingly the MFI of mAbs reactive to HLA-G are almost equal to or higher than those produced with HLA-E, although the immunogen is HLA-EG. Two HLA-E reactive mAbs reacted with either HLA-F (Group G-III) or HLA-G (Group G-IV) at low levels. Figure 1 illustrates some of the amino acid sequences that are common for HLA-Ib isoforms, although these sequences are also found in several but not in all HLA-I alleles. Since we could not decipher specific linear sequences shared among HLA-Ib isoforms, it is inferred that the HLA-Ib specific mAbs may recognize the sequences (in the black boxes) folded in certain unique conformations characteristic for HLA-Ib. Furthermore, the only difference in the amino acid sequences between HLA-EG107 and HLA-ER107 is the presence glycine in the former, and arginine, at position 107 in the latter. Of the total mAbs obtained after immunizing a single mouse with HLA-EG107, nine mAbs are HLA-Ib reactive, whereas only one mAb is reacting to HLA-Ib of the total mAbs obtained after immunizing two mice with HLA-ER107, suggesting that the presence of arginine at 107 in HLA-E may impact the conformational orientation of the HLA-E.

3.4. Expanding Diversity of the HLA-Ia Reactivities of HLA-E*01:01 (HLA-ER) mAbs

3.4.1. HLA-B*4006 But Not HLA-A, HLA-C, HLA-F, and HLA-G Reactive (Group R-III)

Group R-III represented by mAb TFL-114 in Table 4 illustrates a unique feature of allelic specificity, in that it reacted only with B*4006, in addition to recognizing HLA-E.

3.4.2. HLA-B and HLA-C Reactive But Not HLA-A, HLA-F, or HLA-G Reactive (Group R-IV)

Table 4 also illustrates the evolving diversity of the anti-HLA-ER mAbs represented by the subgroups of Group R-IV. This group is HLA-A, HLA-F, and HLA-G non-reactive. Subgroups A, B, C, D, and E in Table 4 illustrate two important aspects of the mAbs. They are (1) the number of alleles recognized by the mAbs progressively increases from subgroup A to E; and similarly, (2) the MFI of these mAbs for each of the alleles also progressively increases from subgroup A to E. Indeed, 27 out of 28 mAbs (except one) recognize B*4006 positively.
Figure 2 sheds light on why Group R-IV is not reactive to HLA-A. The figure shows several shared amino acid sequences among HLA-E, HLA-B, and HLA-C (green band). Subgroups C, D, and E may be recognizing 137DTAAQI142 as evidenced by the alleles carrying this sequence. The sequence 137DTAAQI142 is found in HLA-E/-G/-B and –C, whereas in HLA-A, it is 137DMAAQI142 (Figure 2). As shown in Figure 4, 137DTAAQI142 is evidently a cryptic epitope masked by β2m. Further careful examination of the sequence will reveal that even in the absence of β2M, DTA and DTM are exposed in addition to QI. Therefore, we infer that the R-IV-subgroups, more importantly subgroup E, recognizes 137DTAAQI142. Peptide inhibition of binding of every one of the R-IV subgroup E mAbs with the beadset may validate the inference.
Since HLA-E mAbs may recognize non-linear sequences, it is possible that the anti-HLA-E mAbs recognize unique conformations of the shared amino acid sequences of B*4006 (Figure 5). In support of this suggestion, Figure 6 illustrates the proportional variations in the MFI of the mAbs reacting to HLA-E and B*4006. The ten mAbs in subgroup A of Group R-IV reveal binding affinity for B*4006 and C*1802. Similarly, six mAbs in subgroup B of the Group R-IV show affinity for C*0501 in addition to recognizing B*4006 and C*1802. The 14 mAbs in subgroups C, D, and E show expanded affinity for other alleles of HLA-B and HLA-C isoforms in addition to the stronger binding affinity for B*4006 and C*1802.

3.4.3. HLA-B and HLA-C Reactive but HLA-F, HLA-G Non-Reactive While Having Unique Affinity for HLA-A*1101 (Group R-V)

The expanding diversity of Group R-IV continues into Group V mAbs, as evidenced by the subgroups A, B, C, D, E, F, and G (Table 5). Group R-V mAbs in general recognized a greater number of alleles of HLA-B and HLA-C compared to Group IV. Most importantly, there was no noteworthy decrease in MFIs of HLA-E reactivity despite the expansion into additional allelic recognition. Subgroups A, B, C, D, E, F, and G in Table 5 also illustrate the two important aspects of the mAbs, namely (1) the number of alleles recognized by the mAbs progressively increases from subgroup A to E, and (2) similarly the MFI of these mAbs for each of the alleles also progressively increased from subgroup A to E. The most striking feature of these subgroups is that they also recognized exclusively HLA-A*1101 but not any other HLA-A alleles. Indeed, all the 68 mAbs recognized B*4006 positively, with a progressive increase in MFI from subgroup A to G.

3.4.4. HLA-Ia Reactive but HLA-F, and HLA-G Non-Reactive (Group R-VI)

The diversity of HLA-ER binding mAbs further expands in Group R-VI, to recognize all of HLA-Ia isoforms (HLA-A, HLA-B, and HLA-C), while not recognizing HLA-F and HLA-G (Table 6). We could identify five subgroups of Group VI. Subgroup A recognized A*3303 in addition to A*1101. In subgroup B, not only the MFIs of mAbs recognizing A*1101 increased, but also there was recognition of A*3601 and A*3401, and much more of A-alleles in other subgroups under Group VI. Group VI in general recognized a greater number of alleles of HLA-B and HLA-C.
Despite such high recognition of HLA-Ia alleles, it is interesting to note the failure to recognize HLA-Ib alleles other than that of HLA-E. Only one allele from each HLA-F and HLA-G was tested, and probably more alleles need to be tested to confirm their lack of affinity of HLA-F and HLA-G. Subgroups A, B, C, D. E, and F in Table 6 also illustrate the two important aspects of the mAbs, namely (1) progressive increase in the number of alleles recognized by the mAbs from subgroup A to E, and similarly, (2) the progressive increase of MFI of these mAbs for each of the alleles also from subgroup A to E. Indeed, all the 29 mAbs recognized B*4006 positively, with a progressive increase in MFI from subgroup A to F.

3.5. Expanding Diversity HLA-Ia Reactivity of HLA-EG mAbs

3.5.1. HLA-B Reactive but HLA-A, HLA-C, HLA-F, and HLA-G Non-Reactive (Group G-V)

Four mAbs (TFL-173/174/175/219) represented by Group G-V in Table 7 illustrate a unique feature of allelic specificity not observed earlier among HLA-ER mAbs, that is they reacted only with a few B alleles in addition to HLA-E. Strikingly, TFL-175 recognized B*1511 and B*5201, while the other three mAbs recognized B*5701 in addition. It is important to note that a distinguishing feature of anti-HLA-EG mAbs is that they do not recognize HLA-B*4006, in striking contrast to anti-HLA-ER. Figure 5 shows several shared amino acid sequences between HLA-E and B*1511. Since HLA-E mAbs recognize non-linear sequences, it is possible that the anti-HLA-E mAbs recognize unique conformation of the shared amino acid sequences of B*1511, B*5201 and B*5701.

3.5.2. HLA-Ia Reactive but HLA-F, and HLA-G Non-Reactive (Group G-VI)

Group G-VI in Table 7 further illustrates expansion of allelic recognition of HLA-EG mAbs, which included recognition of A*1101 only among alleles of HLA-A isoforms, very similar to Group R-IV of HLA-ER mAbs. It is important to note a progressive increase in the MFIs of Group VI subgroups concomitant with the increase in MFIs of alleles of B and C loci. Such increase in MFI does not affect the MFIs of HLA-E, suggesting the expansion of allelic recognition together with the increase in the mAbs reactivity. No striking increase in MFI was observed for the mAbs that reached saturation for HLA-E recognition, and there was a need to dilute these mAbs further to assess the increase in the mAb strength at the specified concentration. Serial dilution of the mAbs reveal relative affinity of the mAb for different alleles. Group VII in Table 8 illustrates the same, the mAbs in the subgroups are HLA-Ia reactive but HLA-F and HLA-G are non-reactive. Eleven anti-HLA-EG mAbs in Groups B to D recognized B*4006 at low MFI (<2 K).

3.6. Emergence of Highly Polyreactive mAbs against HLA-E*01:01 and HLA-E*01:03

HLA-Ib Specific mAbs Also Eact with all HLA-Ia Isoform Alleles

HLA-ER as an immunogen has elicited eight HLA-Ib and HLA-Ia reactive antibodies (Table 9). Of these, TFL-069 (R-VII) showed HLA-F reactivity and HLA-A*1101 reactivity in addition to HLA-B and HLA-C reactivities. The MFIs of B*4006 and C*1802 are 7 K and 8 K, respectively. Two mAbs, namely TFL-103 and TFL-104 (R-VIII), failed to react with HLA-F, but reacted well with HLA-G (MFI: 4 K) and with several HLA-A, HLA-B, and HLA-C alleles. Three mAbs showed unique affinity to both HLA-F and HLA-G in addition to HLA-I alleles. Of these mAbs, TFL-049 recognized only HLA-A*1101, four B alleles including B*4006, and three C alleles, including C*1802 (Table 9). The other two mAbs are polyreactive, of which TFL-006 supersedes all anti-HLA mAbs studied so far as being the most highly polyreactive; they recognized 25 A alleles, 45 B alleles, and all the 16 C alleles. Evidently, it recognizes the most common sequences in HLA isoforms located at the α2 helical domain, namely 117AYDGKDY123 and 126LNEDLRSWTA135. Indeed, the synthetic peptide AYDGKDY inhibited the binding of TFL-006 and TFL-007 to HLA-I coated beadsets [36]. Figure 4 illustrates the location of the possible epitopes recognized by TFL-006 and TFL-007.
HLA-EG as an immunogen is strikingly different from HLA-ER in eliciting HLA-Ia and Ib reactivity. Ten mAbs (Group G-VIII) showed reactivity only with HLA-F of HLA-Ib isoforms and with almost all alleles of HLA-Ia isoforms. TFL-235 showed remarkably high reactivity with all HLA-A (n = 31), HLA-B (n = 50), and HLA-C (n = 16) alleles tested, whereas the mAb failed to react with HLA-G. On the other hand, Group G-IX, subgroup A (eight mAbs) showed weak reactivity (MFIs 1 K to 2+ K) with HLA-G, but consistently reacted strongly with HLA-A*1101 and weakly with HLA-A*2402, in addition to reacting with several alleles of HLA-B and HLA-C. Group G-IX, subgroup B (three mAbs) reacted strongly with HLA-G (MFIs: 11–14 K) in addition to moderate reactivity with several alleles of HLA-Ia isoforms. The subgroup C (five mAbs) reacted well with HLA-G, but showed very strong reactivity (MFI 8 K–19 K) with several alleles of HLA-B alleles in addition to their reactivity to several HLA-A and HLA-C alleles. Another striking feature of this group is that four of the five mAbs showed MFI of 10 K to 24 K with C*1802.
Group G-X (four mAbs) is unique in that these mAbs reacted with HLA-F and HLA-G in addition to alleles of all the three HLA-Ia isoforms. TFL-232 showed high reactivity to HLA-G (MFI: 21 K). In addition to its reactivity with A*1101 and A*3402, it showed reactivity with HLA-B and HLA-C. The other three mAbs, while showing positivity to HLA-F and HLA-G, reacted reasonably well with alleles of the three HLA-Ia isoforms. The mAb TFL-198 is strikingly different in that it showed weak reactivity with HLA-G (MFI: 0+), moderate reactivity with most of the HLA-A alleles and very strong reactivity with several of HLA-B and HLA-C alleles. None of these three mAbs of G-X met the amazing polyreactivity of R-X mAb TFL-006, specifically to open conformers (Table 10).

3.7. HLA-I Reactivity in Human Sera

3.7.1. Non-Alloimmunized Males’ Sera Reactivity to HLA-I Alleles Reflects the Profiles of Some of the HLA-E mAbs

Non-alloimmunized males’ sera showing high positivity for anti-HLA-E IgG antibodies were examined for IgG HLA-I reactivity (Table 11). The following aspects of HLA-I reactivity resemble that of HLA-I reactivity of HLA-E mAbs: (1) HLA-A reactivity of 8 out of 11 sera were low or none (1 to 3 alleles). The highest frequency for HLA-A locus specificities is for A*2402; (2) All sera showed high reactivity for HLA-C; (3) The highest HLA-B frequency was observed for B*4006 = B* 3701 > B*8201; (4) The HLA antibody profile of male donor TJ was strikingly similar to that observed in Group R-IV subgroup B mAbs, presented in Table 4; (5) Similarly, the serum antibody profile of HR was somewhat similar to Group R-IV subgroup E, though HLA-C reactivity was high; and (6) the serum Abs of two male donors (VJ and HO) were similar to the profiles of the mAbs G-VII subgroups C and D.

3.7.2. Pattern of HLA-I Reactivity in Melanoma Patients before and after Immunizing with Autologous IFN-gamma Activated Tumor Cells Reflects HLA-E mAb Profiles

Anti-HLA-E Abs in normal human sera may be responsible for antibody reactivity to allo-HLA-Ia alleles. This provides support to the hypothesis that HLA-E is immunogenic in males. HLA-E and HLA-E HCs are more prevalent on tumor cells, including melanoma, as evidenced by immunostaining with the monospecific mAbs TFL-033 and the polyreactive mAb MEM-E/02, which bind to the cryptic epitopes exposed on the heavy chain of HLA-E [37]. It has been established that IFN-gamma significantly increased the surface expression of HLA-E and the shedding of soluble HLA-E by melanoma tumor cells [42,43]. To assess the immunogenicity of tumor associated HLA-E in cancer patients, specifically in stage III and/or stage IV melanoma patients, sera obtained at weeks 0 and 4 after immunizing with the autologous tumor cells activated by IFN-gamma, were examined for the presence of both HLA-E antibodies and HLA-class Ia allelic reactivity. Table 12 documents that autologous tumor cell vaccination augmented the HLA-E IgG antibodies in the sera and concomitant reactivity against several allo-HLA-Ia alleles. The allo-HLA-Ia reactivity of HLA-E Abs in the vaccine sera was confirmed by inhibiting the HLA-E and HLA-Ia reactivity of the sera with peptide sequences shared between HLA-E and HLA-Ia alleles [41].

3.7.3. Pattern of HLA-I Reactivity of HLA-Sensitized ESKD Patients Waiting for Transplantation

In the end-stage organ disease patients with high levels of preformed anti-HLA antibodies (highly sensitized), transplant rates are significantly reduced because of the increased rejection risk [44]. The highly sensitized patient is destined to remain on the waiting list for extended periods on dialysis, an added risk factor which may decrease both graft and patient survival [45,46]. It is often construed that these antibodies result from exposure to non-self HLA antigens, usually from previous transplants, blood transfusions, and/or pregnancies [47]. Examination of the HLA-reactivity in 10 patients with ESKD, was presented in Table 13, it was noted that the profile of the HLA-I reactivity is similar but not identical to any specific anti-HLA-E mAbs. One patient (11DM) showed reactivity to HLA-A* 1101, and several other A and B alleles, similar to anti-HLA-E mAbs (Groups G-VII E and G). Several patients also showed several similarities in the reactivity of HLA-A and B alleles with anti-HLA-E mAbs (Groups G-VII). These observations suggest that the varying reactivity observed in the patients may be a result of antibody response to HLA-E and possibly to other HLA-Ib alleles with high prevalence of open conformers, such as that of HLA-F and HLA-G.

4. Discussion

4.1. Immunogenicity of HLA HCs (Open Conformers) versus Intact HLA (Closed Conformers)

A number of investigators [5,6,7,8,9,10,11,12,13,14,15] have demonstrated that HLA-I molecules not only occur as heterodimers on the cell surface, but also occur as monomers or the β2m-free HCs (open conformers). The HLA-I HCs may be involved in functions other than antigen presentation [15,16,17,18,19,48]. The open conformers of HLA alleles expose amino acid sequences, which are cryptic in intact HLA. Therefore, there is a possibility that the immune system may recognize immunogenic domains on the open conformers as “non-self”. Moreover, the cell surface expression of the open conformers is augmented by inflammation, infection, trauma, and malignancy [5,6,7,8,9,10,11,12,13,14,15,19,48]. The breadth and strength of the HLA antibodies, whether directed against HC open conformers or closed conformers, are augmented by the inflammation stimulated by end-stage organ diseases present in transplant patients, as well as by infection, trauma, malignancy, and the transplantation process itself [49,50].
Following peptide presentation or shedding by trimeric closed conformers, the β2m gets separated from the HLA-I HCs. The dissociated HCs, as well as the naturally occurring open conformer HCs are cleaved from the cell surface by calcium-dependent and zinc-containing matrix metalloproteinases (MMPs) [2] and are shed first into the microenvironment and then into the circulation. Upon shedding of HCs, the HC may get deglycosylated and degraded by proteases. Even if we immunize intact HLA in a human or animal model, it will soon be dissociated and degraded into the circulation. Depending on the duration of the degradation, the HCs that can be recognized by the immune cells to elicit antibody responses. The time frame of degradation may vary with the conformational orientation of the amino acid sequences. The partitioning of the diversified groups and subgroups of mAbs against the HCs of HLA-E*0101 and HLA-E*01:03 outlined above supports the above contention.
The exposure of the cryptic sequences and their fragments may elicit an immune response and result in antibody formation against several such epitopes. One has to visualize the HC of a closed conformer and compare it with that of an open conformer. What is common is that the α1 and α2 domains in the immediate vicinity of the peptide groove are exposed in both closed and open conformers (Figure 3). The amino acids between 80 and 140 of the HC are cryptic in closed conformers. No antibody can recognize them in intact HLA (closed conformers) due to the presence of β2m. However, when the HC is devoid of β2m, as in open conformers these sequences are exposed for immune recognition. That explains the ramification of the mAbs reacting to different HLA-I isoforms. One may argue that the diversity of the mAbs is due to immunization of human HLA-E HC molecules in a non-human (mouse) model. Amazingly (as shown in Figure 1), the amino acid sequence of the murine equivalent of HLA-E, namely Qa1b, shows similarity to HLA-E comparable to that of HLA-F and HLA-G, particularly in the α1 and α2 domains [51]. There is not much variation in the α3 domain among HLA-I, for this domain is highly shared among all HLA-I isoforms.

4.2. HLA-E mAbs Recognizing Private Epitopes

The shed HCs expose two categories of amino acid sequences to be recognized by the immune system. The first category is referred to as “private epitopes”, the sequences specific or unique for an individual isoform or allele. They are the monospecific epitopes. Only the anti-HLA mAbs formed against the monospecific epitopes are reliable for immunodiagnosis of specific HLA-isomers or alleles. Twenty mAbs developed against HLA-ER and five mAbs developed against HLA-E*01:03 (HLA-EG) recognized only HLA-E and not HLA-F or HLA-G or any of the isoforms of HLA-Ia. The monospecific or private epitopes are located in the α1 and α2 domains surrounding the peptide groove (Figure 3). To further clarify, it may be stated that the sequences 65RSARDTA71 and 143SEQKSNDASE152 are found only in HLA-E alleles (e.g., HLA-ER and HLA-EG) and not in any other isoforms (Figure 2 and Figure 3). We have examined more than 500 HLA-A alleles, 800 HLA-B alleles, 280 HLA-C alleles, several HLA-F and HLA-G alleles to ascertain whether 65RSARDTA71 and 143SEQKSNDASE152 are indeed monospecific epitopes or “truly private epitopes” specific for all HLA-E alleles or only HLA-E alleles. Most importantly, we have synthesized the sequences 65RSARDTA71 and 143SEQKSNDASE152 and tested whether they block the binding of one of the monospecific mAbs (TFL-033) to HLA-E coated beads. The dosimetric inhibition of binding confirms the specificity of the epitopes [37]. The sequence between amino acids 65 and 71 differs markedly as follows: 65RSARDTA71 (found only in HLA-E); whereas in HLA-F, it is 65NTKAHA71; in HLA-G, it is 65YAKAHA71; in all C alleles, it is 65KYKRQA71; in B*1501, it is 65ISKTNT71; in B*1510, it is 65ICKTNT71; and in B*1516, it is 65NMKASA71. An examination of the amino acid sequences in this region of the peptide groove of both α1 and α2 sequences reveals the diversity of private epitopes.

4.3. HLA-E mAbs Recognizing Public Epitopes

The other category of HLA-E epitopes is called “public epitopes”, shared by HLA-E and other HLA-Ia and HLA-Ib isoforms. In a thought-provoking review, Tambur and Class attempted to clarify “that every HLA antigen has its own unique combination of epitopes, but at the same time, many of these epitopes are shared with some other HLA antigens” [52]. However, Figure 2A–C illustrates that “many of these epitopes are not just shared with some other HLA antigens” but shared with almost all HLA-I antigens. Figure 2D points out that 117AYDGKDY123 is found in 491 HLA-A, 831 HLA-B and 271 HLA-C alleles, 126LNEDLRSWTA135 in the α2 domain of 239 HLA-A, 219 HLA-B and 261 HLA-C alleles, whereas 137DTAAQI142 is shared by 824 HLA-B and 248 HLA-C alleles; however, the sequence is altered in HLA-A as 137DMAAQI142. Indeed, the sequences 117AYDGKDY123, 126LNEDLRSWTA135 befit the definition of shared or “public epitopes” (see Figure 1 and Figure 2). In the HLA-I α3-domain, a major fraction of the common amino acid sequences are shared by almost all other HLA-I molecules. The public epitopes in the α1 and α2 domain are always masked by β2-m in intact HLA. The β2-m causes steric hindrance for IgG binding; however, these public epitopes are well exposed in open conformers.

4.4. Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 mAbs

An interesting finding is that the two HLA-E alleles used for immunization, namely, HLA-E*01:01 (HLA-ER) and HLA-E*01:03 (HLA-EG) differ by one amino acid substitution at position 107, resulting in an arginine in HLA-E*01:01 (HLA-ER) and glycine in HLA-E*01:03 (HLA-EG) and there are resulting ramifications on HLA-I allelic reactivity. In contrast to HLA-ER, HLA-EG has higher affinity to peptides, higher surface expression, and higher thermal stability, and it is more ancient than HLA-ER, though both alleles are presented in human populations in nearly equal frequencies [53]. Interestingly the ramification of the groups of mAbs generated by the two alleles shows some similarities and several striking differences in the pattern of their HLA-I allelic recognition (Figure 7).
A noteworthy similarity of mAbs developed against both alleles is that they recognize HLA-A*1101 exclusively. In fact, we have categorized mAbs negative (R-IV (30 mAbs) and G-V (4 mAbs)) and positive for HLA-A*1101 (Group R-V (68 mAbs) and G-VI (15 mAbs)). Besides one of the HLA-Ib reactive mAb from HLA-ER recognized HLA-A*1101 exclusively.

4.5. Many HLA-E mAbs May Recognize Conformationally Altered Sequences

Although all HLA isomers possess both monospecific (private epitopes) and shared (public epitopes) amino acid sequences, the conformational variations of the quaternary structure do not retain all sequences in a linear format. Both Figure 3 and Figure 4 illustrate this point clearly. Consequently, monospecific and polyreactive antibodies do not necessarily recognize linear sequences of the monospecific and shared amino acid sequences. There may be subtle variations introduced by folding due to differences in the other neighboring amino acids. This is based on the following findings:
(a)
The only difference in the amino acid sequences of HLA-EG107 and HLA-ER107 is the presence of glycine in the former, and arginine in the later, at position 107. Interestingly, of the total mAbs obtained after immunizing a single mouse with HLA-EG107 or two mice with HLA-ER107, eight mAbs of HLA-EG recognized HLA-F, while only one mAb of HLA-ER recognized HLA-F. While eight mAbs of HLA-EG recognized HLA-G, only one mAb of HLA-ER recognized HLA-G. These observations suggest that the presence of glycine at 107 in HLA-E may impact the conformational orientation of the HLA-E to elicit mAbs reactive to HLA-F and HLA-G.
(b)
The most striking aspect in their allelic recognition is that almost all mAbs (132 out of 133) developed against HLA-E*01:01 (HLA-ER) recognized HLA-B*4006 (Figure 6 and Figure 7). Only 17 anti- HLA-E*01:03 (HLA-EG) mAbs showed low reactivity (<4K) to B*4006. Specific recognition of B*4006 by mAbs belonging to groups R-III and R-IV (Table 4) clearly points out the unique exposure of the conformation of B*4006 comparable to HLA-ER107, that is not observed with Group G, which is possibly due to the presence of glycine at position 107.
(c)
Similarly, HLA-B*1511 is better recognized by the mAbs of HLA-E*01:03 (HLA-EG) than those developed from HLA-ER. The specific recognition of B*1511 by mAbs belonging to groups G-V and G-VI (Table 7) points out the unique exposure of the conformation of B*5011 is comparable to HLA-EG107, in contrast to that of HLA-ER107.
(d)
HLA-C*1802 was recognized by all mAbs of HLA-ER, whereas many mAbs raised against HLA-EG failed to recognize the same allele. Figure 7 diagrammatically illustrates the trends of HLA-I reactivity of the anti-HLA-E*0101 and anti-HLA-E*0103 mAbs.
(e)
Group R-IV (Table 4) anti-HLA-E mAbs bind to HLA-B and C but do not bind to any of the HLA-A alleles, possibly due to the presence of 137DTAAQI142 found in HLA-E/-G/-B and –C), whereas in HLA-A, it is 137DTMAAQI142 (Figure 2). The T138 is replaced by M138. Figure 4 clearly shows the location of DTAAQI, in which only DT and QI are exposed during folding. Replacement of “T’ with “M” alters the immune recognition by the 30 mAbs in R-V.
(f)
Group R-IV mAbs do not bind to HLA-F, for DTAAQI is modified as 137DTVAQI142 in HLA-F.
(g)
Group R-IV mAbs also do not bind to HLA-G due to change in the closely associated neighboring amino acid of DTAAQI, as follows: in HLA-E, the amino acid preceding DTAAQI is V, whereas in HLA-F and HLA-G, the V is replaced with A (for details see Figure 1).
(h)
In 137DTAAQI142, the amino acid in the 136thposition and in the 143rdposition vary markedly, as seen in Figure 2. These changes may impact the exposure of the sequences. Such specific alterations can impact immune recognition by the mAbs.

4.6. Relevance of mAbs to Serum Antibodies of Normal Healthy Humans

Several allo-HLA antibodies are known to occur naturally in the sera of both men and women that have not been alloimmunized by transfusion, prior transplantation, or pregnancy [24,25,26,27,28,29]. Morales–Buenrostro et al. [29] demonstrated the specificities and incidence of the allo-HLA-I Abs in non-alloimmunized males. Neither the origin nor the cause of anti-HLA Abs occurring in healthy individuals have been established. The observations made on the non-alloimmunized sera after purifying with protein-G column, reported in this study, establish the prevalence of anti-HLA-Ia IgG antibodies in the sera of normal, non-alloimmunized individuals. These sera had anti-HLA-E IgG antibodies. It was further observed that the IgG antibodies in the sera recognized several HLA-Ia alleles. The most prevalent alleles recognized by the healthy male sera are B*8201 (n = 13), C*0302 (n = 13), C*0102 (n = 11), B*0702 (n = 10), C* 0303 (n = 9), B*5601 (n = 9), B*4402 (n = 8), C*1701 (n = 8), B*1502 (n = 7), B* 1512 (n = 7), C*1502 (n = 7), C*1203 (n = 7), C*0202 (n = 7), B*3701 (n = 6), C*0501 (n = 6), and C*1802 (n = 6). Interestingly most of these sera reacted with HLA-A alleles as observed with anti-HLA-ER and anti-HLA-EG in Table 4 and Table 6.
In an earlier investigation, the presence of HLA-E and HLA-Ia antibodies in normal sera was validated by using commercially available purified human IgG, obtained from Southern Biotek (Birmingham, AL, USA) [28]. These commercial preparations are made from sera of 4 or 5 normal and healthy volunteers, and the purified normal sera IgG are used as a standard for immunoassays. The analysis revealed reactivity of the commercial human IgG to HLA-B (HLA-B*3701) and six other HLA-C alleles (C*0202, C*0501, C*0602, C*0702, C*1601, and C*1802). The alleles of HLA-Ia exhibiting reactivity to the purified human IgG are strikingly similar to HLA-Ia reactivity observed in normal human sera as well as by anti–HLA-ER mAbs in Group R-IV-C (mAb TFL-093). Based on these findings, we infer that most of the anti-HLA antibodies observed in non-alloimmunized males could be autoantibodies generated in the individual against one’s own HLA open conformers, such as that of HLA-E. Of course, there could be a few monospecific mAbs, directed against private or monospecific epitopes. These human HLA-I antibodies are the consequence of shedding of self HLA open conformers (HCs of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G).
The above inference is also applicable to intravenous immunoglobulin (IVIg), a pharmaceutical preparation of plasma-derived human immunoglobulin G (IgG). It is fractionated from the pooled plasma of 1000 to 60,000 blood donors, including non-alloimmunized donors. Similar to the normal human sera, different IVIg preparations showed a wide variety of reactivity to classic HLA-Ia [54,55,56]. Interestingly, in the previous report, we have ascertained whether the immunoreactivity to HLA-Ia alleles found in IVIg is due to the anti–HLA-E Abs present in IVIg. We have adsorbed out the anti–HLA-E Abs with Sephadex gel conjugated with recombinant HLA-E, then tested for HLA-E and HLA-Ia reactivity. As expected, IVIg immunoreactivity to both HLA-E and HLA-Ia is lost after the adsorbing-out process (see Figure 6A,B in [54]). This previous finding is well supported by the present investigation of anti-HLA-E mAbs.

4.7. HLA-E Polyreactive mAbs (TFL-006 and TFL007) Mimic Immunoreactivity of IVIg

Therapeutically, IVIg is administered to reduce allo-HLA antibodies pre- and post-transplantation, but the mechanism of reduction remains unclear. We have compared the efficacy of IVIg and the Group R-X mAb TFL-007, which mimics the HLA-Ia and HLA-Ib reactivity of IVIg in suppressing both antibody production [57] and blastogenesis and proliferation of CD4+ T cells [58]. The mAb-007 significantly suppressed the allo-HLA class-II IgG produced by the B cells, and this suppression was far superior to that by IVIg [55,56]. These findings were confirmed with HLA-I antibody secreted by an immortalized B cell line, developed from the blood of another alloimmunized woman [57]. The binding of the mAb TFL-007 to peptide sequences shared (i.e., shared epitopes) between HLA-Ib and β2m-free HLA HCs (open conformers) on the cell surface of B cells may act as a ligand that induces suppression of IgG production of activated B memory cells.

4.8. Profiles of HLA-Ia Reactivity of Anti-HLA-E IgG in Melanoma Patients Reflect the HLA-I Reactivity of Some of the Anti-HLA-E mAbs

Melanoma patients’ sera contain IgG antibodies against HLA-E as well as HLA-B and HLA-C. Interestingly, the HLA-I reactivity in the patients’ sera strongly recalls the pattern observed in Groups R-IV and G-V in that the sera are totally negative for HLA-A alleles. Indeed, the vaccination with autologous tumor cells augmented the MFIs of HLA-E and several other HLA-Ia alleles. However, the pattern of allo-HLA-Ia allelic reactivity of the post-vaccination sera is identical to that observed in pre-immune sera. No new allo-HLA-Ia allelic reactivity was observed in any of the patients after immunization with autologous tumor cell vaccine.

4.9. Profiles of HLA-Ia Reactivity of Sensitized Sera of ESKD Patients Reflect the HLA-I Reactivity of the Anti-HLA-E mAbs

The HLA-I reactivity of sensitized patients waiting for donor organs is strikingly different from the normal and melanoma patients’ sera. Sensitized patients showed antibodies for HLA-A*0101, HLA-A*0201, HLA-A*0203, and HLA-A*0301. Among mAbs raised against HLA-ER and HLA-EG, two mAbs in Group R-X (TFL-006 and TFL-007), two mAbs in Group G-VII (mAbs TFL-171 and TFL-172), and one in G-GVIII (TFL-235) showed the reactivity to all these alleles. These findings emphasize that the HLA sensitization, as monitored by measuring the strength of HLA antibodies, is a consequence of immune recognition of HLA open conformer on the surface of cells activated by inflammation, infection, and traumas. Furthermore, these findings can be extended to post-transplantation since transplant surgery per se is an inflammation inducer leading to immune recognition of HLA open conformers [49].

5. Conclusions

The ramification of HLA-Ia reactivity of the diverse mAbs generated by immunization of the HCs of one HLA-E allele points out the complexity of HLA-I antibodies. This study emphasizes the need to undertake such studies with HLA-F and HLA-G alleles for the purposes of both comparison and elucidation of the patterns of diversity. Correlating the diverse HLA-Ia and HLA-Ib reactivity patterns of serum antibodies after infection, inflammation, autoimmune diseases, and in different cancers and end-stage organ diseases may provide clues to the primary immunogen and the source of the immunogen involved in these diseases. This would be particularly valuable for patients with various cancers and end-stage organ diseases.
Poet William Wordsworth once said that “one impulse from a vernal wood may teach you more of man, of moral evil and of good, than all the sages can.” We conclude from this investigation that “one heavy chain of an HLA exposed to an immune system may reveal the origin and ramifications of human HLA antibodies, their good and bad potentials, than all the transplant and cancer clinicians can envisage”.

Author Contributions

Conceptualization, M.H.R. and N.M.R.; methodology, M.H.R. and M.H.R.; software, M.H.R.; validation, M.H.R., N.M.R. and S.R.S.; formal analysis, S.R.S., E.J.F. and F.E.H.; investigation, M.H.R.; resources, M.H.R.; data curation, M.H.R.; writing—original draft preparation, M.H.R.; writing—review and editing, M.H.R., E.J.F., S.R.S. and F.E.H.; visualization, M.H.R.; supervision, M.H.R.; project administration, M.H.R.; funding acquisition, M.H.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study primarily involves mice and the immunization was carried out at One Lambda Inc. (Canoga Park, Los Angeles, CA, USA) and does not require Institutional Review board statement.

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study. For each cohort the details of informed consent statement is provided in Section 2.3, Section 2.4 and Section 2.5.

Data Availability Statement

The original data is available at Terasaki Foundation Laboratory.

Acknowledgments

M.H.R. is indebted to the late Paul Ichiro Terasaki for his invaluable discussions during the course of this investigation. We sincerely thank Vadim Jucaud and Tho Pham, research associates at Terasaki Foundation laboratory for meticulously carrying out the SAB assays. Finally, we want thank Mark Terasaki for his constant support and encouragement. The mAbs TFL-033, TFL-034, TFL-073, and TFL-07 4 (monospecific mAbs), and TFL-006 and TFL-007 were patented. The mAbs TFL-033 and TFL-006 were deposited with ATCC. The rest of the mAbs are cryopreserved at Terasaki Research Institute, Los Angeles and monitored by Vadim Jucaud and Tho Pham.

Conflicts of Interest

Senthamil R. Selvan is is an employee of Tetracore Inc. The authors declare no conflicts of interest.

Abbreviations

Abs: antibodies; Ag: antigen; β2m: beta-2 microglobulin; HLA: human leukocyte antigens; HC: heavy chain; mAb: monoclonal antibodies; MFI: mean fluorescent intensity; MMP: matrix metalloproteinases; NK cells: natural killer cells; SAB: single antigen bead.

References

  1. Townsend, A.; Bodmer, H. Antigen recognition by class I-restricted T lymphocytes. Ann. Rev. Lmmunol. 1989, 7, 601–624. [Google Scholar] [CrossRef] [PubMed]
  2. Rizzo, R.; Trentini, A.; Bortolotti, D.; Manfrinato, M.C.; Rotola, A.; Castellazzi, M.; Melchiorri, L.; Di Luca, D.; Dallocchio, F.; Fainardi, E.; et al. Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding. Mol. Cell. Biochem. 2013, 381, 243–255. [Google Scholar] [CrossRef] [PubMed]
  3. Silva, Z.; Ferro, T.; Almeida, D.; Soares, H.; Ferreira, J.A.; Deschepper, F.M.; Hensbergen, P.J.; Pirro, M.; van Vliet, S.J.; Springer, S.; et al. MHC Class I Stability is Modulated by Cell Surface Sialylation in Human Dendritic Cells. Pharmaceutics 2020, 12, 249. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Ladasky, J.J.; Shum, B.P.; Canavez, F.; Seuanez, H.N.; Parham, P. Residue 3 of β2- microglobulin affects binding of class I MHC molecules by the W6/32 antibody. Immunogenetics 1999, 49, 312–320. [Google Scholar] [CrossRef]
  5. Giacomini, P.; Beretta, A.; Nicotra, M.R.; Ciccarelli, G.; Martayan, A.; Cerboni, C.; Lopalco, L.; Bini, D.; Delfino, L.; Ferrara, G.B.; et al. HLA-C heavy chains free of beta2-microglobulin: Distribution in normal tissues and neoplastic lesions of non-lymphoid origin and interferon-y responsiveness. Tissue Antigens 1997, 50, 555–566. [Google Scholar] [CrossRef]
  6. Raine, T.; Brown, D.; Bowness, P.; Gaston, J.S.H.; Moffett, A.; Trowsdale, J.; Allen, R. Consistent patterns of expression of HLA class I free heavy chains in healthy individuals and raised expression in spondyloarthropathy patients point to physiological and pathological roles. Rheumatology 2006, 45, 1338–1344. [Google Scholar] [CrossRef] [Green Version]
  7. Marozzi, A.; Meneveri, R.; Bunone, G.; De Santis, C.; Lopalco, L.; Beretta, A.; Agresti, A.; Siccardi, A.G.; Della Valle, G.; Ginelli, E. Expression of beta 2m-free HLA class I heavy chains in neuroblastoma cell lines. Scand. J. Immunol. 1993, 37, 661–667. [Google Scholar]
  8. Schnabl, E.; Stockinger, H.; Majdic, O.; Gaugitsch, H.; Lindley, I.J.; Maurer, D.; Hajek-Rosenmayr, A.; Knapp, W. Activated human T lymphocytes express MHC class I heavy chains not associated with beta 2-microglobulin. J. Exp. Med. 1990, 171, 1431–1442. [Google Scholar] [CrossRef]
  9. Madrigal, J.A.; Belich, M.P.; Benjamin, R.J.; Little, A.M.; Hildebrand, W.H.; Mann, D.L.; Parham, P. Molecular definition of a polymorphic antigen (LA45) of free HLA-A and -B heavy chains found on the surfaces of activated B and T cells. J. Exp. Med. 1991, 174, 1085–1095. [Google Scholar] [CrossRef] [Green Version]
  10. Demaria, S.; Schwab, R.; Bushkin, Y. The origin and fate of beta 2m-free MHC class I molecules induced on activated T cells. Cell. Immunol. 1992, 142, 103–113. [Google Scholar] [CrossRef]
  11. Pickl, W.F.; Holter, W.; Stöckl, J.; Majdic, O.; Knapp, W. Expression of beta 2-microglobulin-free HLA class I alpha-chains on activated T cells requires internalization of HLA class I heterodimers. Immunology 1996, 88, 104–109. [Google Scholar] [CrossRef] [PubMed]
  12. Martayan, A.; Fiscella, M.; Setini, A.; Ciccarelli, G.; Gambari, R.; Feriotto, G.; Beretta, A.; Siccardi, A.G.; Appella, E.; Giacomini, P. Conformation and surface expression of free HLA-CW1 heavy chains in the absence of beta 2-microglobulin. Hum. Immunol. 1997, 53, 23–33. [Google Scholar] [CrossRef]
  13. Tsai, W.C.; Chen, C.J.; Yen, J.H.; Ou, T.T.; Tsai, J.J.; Liu, C.S.; Liu, H.W. Free HLA class I heavy chain-carrying monocytes--a potential role in the pathogenesis of spondyloarthropathies. J. Rheumatol. 2002, 29, 966–972. [Google Scholar] [PubMed]
  14. Goodridge, J.P.; Burian, A.; Lee, N.; Geraghty, D.E. HLA-F and MHC Class I Open Conformers Are Ligands for NK Cell Ig-like Receptors. J. Immunol. 2013, 191, 3553–3562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Burian, A.; Wang, K.L.; Finton, K.A.; Lee, N.; Ishitani, A.; Strong, R.K.; Geraghty, D.E. HLA-F and MHC-I Open Conformers Bind Natural Killer Cell Ig-Like Receptor KIR3DS1. PLoS ONE 2016, 11, e0163297. [Google Scholar] [CrossRef] [PubMed]
  16. Garcia-Beltran, W.F.; Hölzemer, A.; Martrus, G.; Chung, A.; Pacheco, Y.; Simoneau, C.R.; Rucevic, M.; Lamothe-Molina, P.A.; Pertel, T.; Kim, T.E.; et al. Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1. Nat. Immunol. 2016, 17, 1067–1074. [Google Scholar] [CrossRef]
  17. Geng, J.; Altman, J.D.; Krishnakumar, S.; Raghavan, M. Empty conformers of HLA-B preferentially bind CD8 and regulate CD8(+) T cell function. Elife 2018, 7, e36341. [Google Scholar] [CrossRef]
  18. Lin, A.; Yan, W.-H. The emerging roles of human leukocyte antigen-F in immune modulation and viral infection. Front. Immunol. 2019, 10, 964. [Google Scholar] [CrossRef]
  19. Arosa, F.A.; Esgalhado, A.J.; Reste-Ferreira, D.; Cardoso, E.M. Open MHC Class I Conformers: A Look through the Looking Glass. Int. J. Mol. Sci. 2021, 22, 9738. [Google Scholar] [CrossRef]
  20. Perosa, F.; Luccarelli, G.; Prete, M.; Favoino, E.; Ferrone, S.; Dammacco, F. Beta 2-microglobulin-freeHLA class Iheavy chain epitope mimicry by monoclonal antibody HC-10-specificpeptide. J. Immunol. 2003, 171, 1918–1926. [Google Scholar] [CrossRef] [Green Version]
  21. Ametani, A.; Apple, R.; Bhardwaj, V.; Gammon, G.; Miller, A.; Sercarz, E. Examining the crypticity of antigenic determinants. Cold Spring Harb. Symp. Quant. Biol. 1989, 54, 505–511. [Google Scholar] [CrossRef] [PubMed]
  22. Gammon, G.; Sercarz, E.E.; Benichou, G. The dominant self and the cryptic self: Shaping the autoreactive T-cell repertoire. Immunol. Today 1991, 12, 193–195. [Google Scholar] [CrossRef]
  23. Sercarz, E.E.; Lehmann, P.V.; Ametani, A.; Benichou, G.; Miller, A.; Moudgil, K. Dominance and crypticity of T cell antigenic determinants. Ann. Rev. Immunol. 1993, 11, 729–766. [Google Scholar] [CrossRef]
  24. Tongio, M.M.; Falkenrodt, A.; Mitsuishi, Y.; Urlacher, A.; Bergerat, J.P.; North, M.L.; Mayer, S. Natural HLA Abs. Tissue Antigens 1985, 26, 271–285. [Google Scholar] [CrossRef] [PubMed]
  25. Zhou, B.; Saito, S.; Nakazawa, Y.; Kobayashi, N.; Matsuda, M.; Matsumoto, Y.; Hosoyama, T.; Koike, K. Existence of an immunoglobulin G component of naturally-occurring HLA Class I Abs that are not directed against self-Ags in human serum. Tissue Antigens 2008, 72, 98–104. [Google Scholar] [CrossRef] [Green Version]
  26. Luscher, M.A.; Choy, G.; Embree, J.E.; Nagelkerke, N.J.; Bwayo, J.J.; Njenga, S.; Plummer, F.A.; Barber, B.H.; Macdonald, K.S. Anti-HLA alloAb is found in children but does not correlate with a lack of HIV type 1 transmission from infected mothers. AIDS Res. Hum. Retrovir. 1998, 14, 99–107. [Google Scholar] [CrossRef]
  27. Májský, A. Natural HLA-A, B and DR Abs in the serum of nonallo-immunized men. Vnitr. Lek. 1989, 35, 467–471. [Google Scholar]
  28. Ravindranath, M.H.; Kaneku, H.; El-Awar, N.; Morales-Buenrostro, L.E.; Terasaki, P.I. Antibodies to HLA-E in non-alloimmunized Males: Pattern of HLA-Ia-reactivity of anti–HLA-E–positive sera. J. Immunol. 2010, 185, 1935–1948. [Google Scholar] [CrossRef] [Green Version]
  29. Morales-Buenrostro, L.E.; Terasaki, P.I.; Marino-Vázquez, L.A.; Lee, J.H.; El-Awar, N.; Alberú, J. “Natural” human leukocyte Ag Abs found in non-allo-immunized healthy males. Transplantation 2008, 86, 1111–1115. [Google Scholar] [CrossRef]
  30. Jucaud, V.; Ravindranath, M.H.; Terasaki, P.I. Conformational Variants of the Individual HLA-I Antigens on Luminex Single Antigen Beads Used in Monitoring HLA Antibodies: Problems and Solutions. Transplantation 2017, 101, 764–777. [Google Scholar] [CrossRef]
  31. Ravindranath, M.H.; Jucaud, V.; Ferrone, S. Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. J. Immunol. Methods 2017, 450, 73–80. [Google Scholar] [CrossRef] [PubMed]
  32. Ravindranath, M.H.; Taniguchi, M.; Chen, C.W.; Ozawa, M.; Kaneku, H.; El-Awar, N.; Cai, J.; Terasaki, P.I. HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: Relevance to human natural HLA antibodies. Mol. Immunol. 2010, 47, 121–131. [Google Scholar] [CrossRef] [PubMed]
  33. Ravindranath, M.H.; Pham, T.; El-Awar, N.; Kaneku, H.; Terasaki, P.I. Anti-HLA-E mAb 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: Web-tools validate the immunogenic epitopes of HLA-E recognized by the Abs. Mol. Immunol. 2011, 48, 423–430. [Google Scholar] [CrossRef]
  34. Ward, P.A.; Adams, J.; Faustman, D.; Gebhart, G.F.; Geistfeld, J.G.; Imbaratto, J.W.; Peterson, N.C.; Quimbey, F.; Marshak-Rothstein, A.; Rowan, A.N.; et al. Monoclonal Antibody Production; National Academy Press: Washington, DC, USA, 1999; pp. 1–47. [Google Scholar]
  35. Ravindranath, M.H.; Terasaki, P.I. Diagnostic and Therapeutic Potential of HLA-E Monospecific Monoclonal IgG Antibodies Directed against Tumor Cell Surface and Soluble HLA-E. U.S. Patent 10656156, 5 July 2012. [Google Scholar]
  36. Ravindranath, M.H.; Terasaki, P.I. Anti-HLA Class-IB Antibodies Mimic Immunoreactivity and Immunomodulatory Functions of Intravenous Immunoglobulin (IVIG) Useful as Therapeutic IVIG Mimetics and Methods of Their Use. International Patent WO 2013/106586 A2, 19 July 2013. [Google Scholar]
  37. Ravindranath, M.H.; Terasaki, P.I.; Pham, T.; Jucad, V. The monospecificity of novel anti-HLA-E monoclonal antibodies enables reliable immunodiagnosis, immunomodulation of HLA-E and upregulation of CD8+ T lymphocytes. Monoclon. Antibodies Immunodiag. Immunother. 2015, 34, 134–153. [Google Scholar] [CrossRef]
  38. Ravindranath, M.H.; Flippone, E.J.; Mahowald, G.; Callender, C.; Babu, A.; Saidman, S.; Ferrone, S. Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different SABs monitored with two different secondary antibodies on a Luminex platform. Immunol. Res. 2018, 66, 584–604. [Google Scholar] [CrossRef] [Green Version]
  39. Ravindranath, M.H.; Ravindranath, N.M.; Amato-Menker, C.J. Luminex multiplex bead assay monitoring HLA IgG antibodies in sensitized pre- and post-transplant patients: Clonality of the detection antibody impacts specificity and sensitivity. Appl. Sci 2021, 11, 6430. [Google Scholar] [CrossRef]
  40. Selvan, S.R.; Dillman, D.O.; Fowler, A.W.; Carbonell, D.J.; Ravindranath, M.H. Monitoring response to treatment in melanoma patients: Potential of a serum glycomic marker. Int. J. Cancer 2008, 122, 1374–1383. [Google Scholar] [CrossRef]
  41. Ravindranath, M.H.; Selvan, S.R.; Terasaki, P.I. Augmentation of anti-HLA-E antibodies with concomitant HLA-Ia reactivity in IFNγ-treated autologous melanoma cell vaccine recipients. J. Immunotoxicol. 2012, 9, 282–291. [Google Scholar] [CrossRef] [Green Version]
  42. Derré, L.; Corvaisier, M.; Charreau, B.; Moreau, A.; Godefroy, E.; Moreau-Aubry, A.; Jotereau, F.; Gervois, N. Expression and release of HLA-E by melanoma cells and melanocytes: Potential impact on the response of cytotoxic effector cells. J. Immunol. 2006, 177, 3100–3107. [Google Scholar] [CrossRef] [Green Version]
  43. Coupel, S.; Moreau, A.; Hamidou, M.; Horejsi, V.; Soulillou, J.P.; Charreau, B. Expression and release of sHLA-E is an immunoregulatory feature of EC activation. Blood 2007, 109, 2806–2814. [Google Scholar] [CrossRef] [Green Version]
  44. Jordan, S.C.; Tyan, D.; Stablein, D.; McIntosh, M.; Rose, S.; Vo, A.; Toyoda, M.; Davis, C.; Shapiro, R.; Adey, D.; et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IGO2 trial. J. Am. Soc. Nephrol. 2004, 15, 3256–3262. [Google Scholar] [CrossRef]
  45. Meier-Kriesche, H.U.; Port, F.K.; Ojo, A.O.; Rudich, S.M.; Hanson, J.A.; Cibrik, D.M.; Leichtman, A.B.; Kaplan, B. Effect of waiting time on renal transplant outcome. Kidney Int. 2000, 58, 1311–1317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Kaplan, B.; Schold, J.; Meier-Kriesche, H.U. Overview of large database analysis in renal transplantation. Am. J. Transpl. 2003, 3, 1052–1056. [Google Scholar] [CrossRef] [PubMed]
  47. Jordan, S.; Cunningham-Rundles, C.; McEwan, R. Utility of intravenous immune globulin in kidney transplantation: Efficacy, safety, and cost implications. Am. J. Transpl. 2003, 3, 653–664. [Google Scholar] [CrossRef]
  48. Arosa, F.A.; Santos, S.G.; Powis, S.J. Open conformers: The hidden Face of MHC-I molecules. Trends Immunol. 2007, 28, 115–123. [Google Scholar] [CrossRef]
  49. Ravindranath, M.H.; EL Hilali, F.; Filippone, E.J. The Impact of Inflammation on the Immune Responses to Transplantation: Tolerance or Rejection? Front. Immunol. 2021, 12, 667834. [Google Scholar] [CrossRef]
  50. Ravindranath, M.H.; Ravindranath, N.M.; Selvan, S.R.; Filippone, E.J.; Amato-Menker, C.J.; El Hilali, F. Four Faces of cell-surface HLA Class-I: Their antigenic and immunogenic divergence generating novel targets for Vaccines. Vaccines 2022, in press. [Google Scholar] [CrossRef] [PubMed]
  51. Zeng, L.; Sullivan, L.C.; Vivian, J.P.; Walpole, N.G.; Harpur, C.M.; Rossjohn, J.; Clements, C.S.; Brooks, A.G. A structural basis of antigen presentation by the MHC class Ib molecule, Qa1. J. Immunol. 2012, 188, 302–310. [Google Scholar] [CrossRef] [Green Version]
  52. Tambur, A.R.; Claas, F.H.J. HLA Epitopes as Viewed by Antibodies: What is it All About? Am. J. Transplant. 2015, 15, 1148–1154. [Google Scholar] [CrossRef] [PubMed]
  53. Kanevskiy, L.; Erokhina, S.; Kobyzeva, P.; Streltsova, M.; Sapozhnikov, A.; Kovalenko, E. Dimorphism of HLA-E and Its Disease Association. Int. J. Mol. Sci. 2019, 20, 5496. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Ravindranath, M.H.; Terasaki, P.I.; Pham, T.; Jucaud, V.; Kawakita, S. Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E Abs that react with HLA-Ia (HLA-A/-B/-Cw) alleles. Blood 2013, 121, 2013–2028. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. EL Hilali, F.; Jucaud, V.; EL Hilali, H.; Bhuiyan, M.H.; Mancuso, A.; LiuSullivan, N.; Elidrissi, A.; Mazouz, H. Characterization of the Anti-HLA Class I and II IgG Antibodies in Moroccan IVIg Using Regular Beads and Ibeads in Luminex Multiplex Single Antigen Immunoassay. Int. J. Immunol. 2017, 5, 53–65. [Google Scholar] [CrossRef] [Green Version]
  56. Ravindranath, M.H.; EL Hilali, F.; Filippone, E.J. Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg. Vaccines 2021, 9, 680. [Google Scholar] [CrossRef] [PubMed]
  57. Zhu, D.; Ravindranath, M.H.; Terasaki, P.I.; Miyazaki, T.; Pham, T.; Jucaud, V. Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: Intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg. Clin. Exp. Immunol. 2014, 177, 464–477. [Google Scholar] [CrossRef] [PubMed]
  58. Ravindranath, M.H.; Terasaki, P.I.; Pham, T.; Jucaud, V.; Kawakita, S. Suppression of blastogenesis and proliferation of activated CD4(+) T cells: Intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg. Clin. Exp. Immunol. 2014, 178, 154–177. [Google Scholar] [CrossRef] [PubMed]
Antibodies 11 00018 g001 550
Figure 1. Comparative profile of the amino acid sequences of HLA-E, HLA-G, and HLA-F, and a partial profile of the sequences of mice equivalent of HLA-E, known as Qa1b. The amino acid sequences of HLA-E are compared with the amino acid sequences of HLA-G and HLA-F, and also with 504 HLA-A, 844 HLA-B, and 283 HLA-C alleles, to determine the HLA-E specific sequences. The HLA-E specific sequences in α1 and α2 helical domains are shown within the red boxes. HLA-Ib shared epitopes area are shown in black and blue boxes. Sequences in the blue boxes are shared with all HLA-Ia isoforms, while those in black boxes are shared with most, if not all, HLA-Ia alleles.
Figure 1. Comparative profile of the amino acid sequences of HLA-E, HLA-G, and HLA-F, and a partial profile of the sequences of mice equivalent of HLA-E, known as Qa1b. The amino acid sequences of HLA-E are compared with the amino acid sequences of HLA-G and HLA-F, and also with 504 HLA-A, 844 HLA-B, and 283 HLA-C alleles, to determine the HLA-E specific sequences. The HLA-E specific sequences in α1 and α2 helical domains are shown within the red boxes. HLA-Ib shared epitopes area are shown in black and blue boxes. Sequences in the blue boxes are shared with all HLA-Ia isoforms, while those in black boxes are shared with most, if not all, HLA-Ia alleles.
Antibodies 11 00018 g001
Antibodies 11 00018 g002a 550Antibodies 11 00018 g002b 550
Figure 2. Comparative profile of the amino acid sequences of HLA-Ia alleles (HLA-A, HLA-B, and HLA-C) and HLA-Ib (HLA-E, HLA-F, and HLA-G) isoforms: HLA-Ia and HLA-Ib shared sequences and HLA-Ib and HLA-Band HLA-C shared sequences coated on the microbeads of LABScreen beadsets. (A) HLA-E,-F,-G compared with 30 alleles HLA-A coated on the LABScreen beadset; (B) 58 alleles HLA-B coated on the LABScreen beadset; (C) 15 alleles HLA-C coated on the LABScreen beadset; and (D) HLA-E amino acid sequences shared with HLA-Ia and HLA-Ib alleles.
Figure 2. Comparative profile of the amino acid sequences of HLA-Ia alleles (HLA-A, HLA-B, and HLA-C) and HLA-Ib (HLA-E, HLA-F, and HLA-G) isoforms: HLA-Ia and HLA-Ib shared sequences and HLA-Ib and HLA-Band HLA-C shared sequences coated on the microbeads of LABScreen beadsets. (A) HLA-E,-F,-G compared with 30 alleles HLA-A coated on the LABScreen beadset; (B) 58 alleles HLA-B coated on the LABScreen beadset; (C) 15 alleles HLA-C coated on the LABScreen beadset; and (D) HLA-E amino acid sequences shared with HLA-Ia and HLA-Ib alleles.
Antibodies 11 00018 g002aAntibodies 11 00018 g002b
Antibodies 11 00018 g003 550
Figure 3. (A,B) represent the two different conformational orientations of HLA-E specific amino acid sequences exposed on α1 and α2 helices of HLA-E. Note a brown colored peptide sequence in the groove. The monospecific epitopes are on either side of the grove. These sequences are recognized by TFL-033 as evidenced by the binding inhibition of the mAb to the beadsets coated with HLA-E after incubation with the peptide sequences, synthesized and obtained commercially (GenScript Corporation, Piscataway, NJ, USA). It is important to note that the mAb recognizes the sequences, which are not linear but folded and exposing few amino acids (colored yellow) of the epitope for immune recognition; this is an important characteristics of HLA-E mAbs.
Figure 3. (A,B) represent the two different conformational orientations of HLA-E specific amino acid sequences exposed on α1 and α2 helices of HLA-E. Note a brown colored peptide sequence in the groove. The monospecific epitopes are on either side of the grove. These sequences are recognized by TFL-033 as evidenced by the binding inhibition of the mAb to the beadsets coated with HLA-E after incubation with the peptide sequences, synthesized and obtained commercially (GenScript Corporation, Piscataway, NJ, USA). It is important to note that the mAb recognizes the sequences, which are not linear but folded and exposing few amino acids (colored yellow) of the epitope for immune recognition; this is an important characteristics of HLA-E mAbs.
Antibodies 11 00018 g003
Antibodies 11 00018 g004 550
Figure 4. (A) The conformational orientation of HLA-E clarifying the location of TFL-006/TFL-007 binding domain (in yellow) in all HLA class I molecule. (B) Figure illustrates the steric hinderence caused by β2-microglobulin (blue); therefore 117AYDGKDY123, is a cryptic epitope not accessible in intact HLA molecules (closed conformers); (C) Figure illustrates exposure of 17AYDGKDY123 on β2-m-free heavy chains of HLA (open conformers).
Figure 4. (A) The conformational orientation of HLA-E clarifying the location of TFL-006/TFL-007 binding domain (in yellow) in all HLA class I molecule. (B) Figure illustrates the steric hinderence caused by β2-microglobulin (blue); therefore 117AYDGKDY123, is a cryptic epitope not accessible in intact HLA molecules (closed conformers); (C) Figure illustrates exposure of 17AYDGKDY123 on β2-m-free heavy chains of HLA (open conformers).
Antibodies 11 00018 g004
Antibodies 11 00018 g005 550
Figure 5. The amino acid sequences of HLA-E compared with the unique B (B*4006, B*1511) or C (C*1802) alleles recognized by a few HLA-ER or HLA-EG mAbs. The asterix in the figure illustrates amino acids, and sequences shared between HLA-E and B*4006 or B*1511 or C*1802.
Figure 5. The amino acid sequences of HLA-E compared with the unique B (B*4006, B*1511) or C (C*1802) alleles recognized by a few HLA-ER or HLA-EG mAbs. The asterix in the figure illustrates amino acids, and sequences shared between HLA-E and B*4006 or B*1511 or C*1802.
Antibodies 11 00018 g005
Antibodies 11 00018 g006 550
Figure 6. MFI of mAbs reacting to HLA-ER and B*4006, a major HLA-Ia antigen recognized by almost all mAbs.
Figure 6. MFI of mAbs reacting to HLA-ER and B*4006, a major HLA-Ia antigen recognized by almost all mAbs.
Antibodies 11 00018 g006
Antibodies 11 00018 g007 550
Figure 7. Diagrammatic illustration of the ramification of HLA-I reactivity of the anti-HLA-E*0101 and anti-HLA-E*0103 mAbs.
Figure 7. Diagrammatic illustration of the ramification of HLA-I reactivity of the anti-HLA-E*0101 and anti-HLA-E*0103 mAbs.
Antibodies 11 00018 g007
Table
Table 1. Diverse HLA class-I isoform reactivity of the monoclonal antibodies generated against two alleles of recombinant HLA-E heavy chains.
Table 1. Diverse HLA class-I isoform reactivity of the monoclonal antibodies generated against two alleles of recombinant HLA-E heavy chains.
ImmunogenGroupsReactivity of Monoclonal Antibodies with HLA-I AllelesNumber of mAbs
HLA-IaHLA-Ib
HLA-AHLA-BHLA-CHLA-EHLA-FHLA-G
HLA-ER107R-INegativeNegativeNegativePositiveNegativeNegative20
R-IINegativeNegativeNegativePositivePositivePositive1
R-IIINegativeB*4006+NegativePositiveNegativeNegative1
R-IVNegativePositivePositivePositiveNegativeNegative30
R-VA*1101+PositivePositivePositiveNegativeNegative68
R-VIPositivePositivePositivePositiveNegativeNegative29
R-VIIA*1101+PositivePositivePositivePositiveNegative1
R-VIIIPositivePositivePositivePositiveNegativePositive2
R-IXA*1101+PositivePositivePositivePositivePositive1
R-XPositivePositivePositivePositivePositivePositive2
HLA-EG107G-INegativeNegativeNegativePositiveNegativeNegative5
G-IINegativeNegativeNegativePositivePositivePositive7
G-IIINegativeNegativeNegativePositivePositiveNegative1
G-IVNegativeNegativeNegativePositiveNegativePositive1
G-VNegativePositiveNegativePositiveNegativeNegative4
G-VIA*1101+PositivePositivePositiveNegativeNegative15
G-VIIPositivePositivePositivePositiveNegativeNegative25
G-VIIIPositivePositivePositivePositivePositiveNegative10
G-IXPositivePositivePositivePositiveNegativePositive16
G-XPositivePositivePositivePositivePositivePositive4
Table
Table 2. HLA-E monospecific mAbs identified with their hybridoma and subclass, produced after immunizing mice with recombinant (non-glycosylated); HLA-ER107 and HLA-EG107 heavy chains.
Table 2. HLA-E monospecific mAbs identified with their hybridoma and subclass, produced after immunizing mice with recombinant (non-glycosylated); HLA-ER107 and HLA-EG107 heavy chains.
GroupsNumber of mAbsmAb NomenclatureHybridoma IDAntigen (Heavy Chain only) Tested on BeadsSubclassHLA-E Reactivity in MFI
(Shorter Version of MFI)		HLA-F Reactivity (MFI)HLA-G Reactivity (MFI)HLA-A Reactivity (MFI)HLA-B Reactivity (MFI)HLA-C Reactivity (MFI)
R-I1TFL-147FA5746-30F1C8HLA-ERIgG122,829 (22+)00000
2TFL-148FA5746-30F1D10HLA-ERIgG116,644 (16+)00000
3TFL-110FT5742-14B1G2HLA-ERNT16,226 (16)00000
4TFL-034FT5742-8C6F6HLA-ERIgG113,272 (13)00000
5TFL-125FA5746-14A5E9HLA-ERIgG113,204 (13)00000
6TFL-033FT5742-8C6F4HLA-ERIgG113,025 (13)00000
7TFL-126FA5746-14A5F12HLA-ERIgG112,397 (12)00000
8TFL-074FT5742-20E2E9HLA-ERIgG110,269 (10)00000
9TFL-073FT5742-20E2G7HLA-ERIgG110,088 (10)00000
10TFL-144FA5746-28D10C6HLA-ERIgG19180 (9)00000
11TFL-041FT5742-11B4A2HLA-ERIgG18914 (8+)00000
12TFL-043FT5742-11B7F12HLA-ERIgG18448 (8)00000
13TFL-145FA5746-29B1C10HLA-ERIgG17622 (7+)00000
14TFL-042FT5742-11B4A6HLA-ERIgG17452 (7)00000
15TFL-182FA5746-32D10D2HLA-ERIgG17280 (7)00000
16TFL-001FT5742-1A1E2HLA-ERIgG2a4691 (4+)00000
17TFL-081FT5742-23F8C12HLA-ERIgG14261 (4)00000
18TFL-016FT5742-4F8F12HLA-ERIgG2a1349 (1)00000
19TFL-047FT5742-12B4E10HLA-ERNK1044 (1)00000
20TFL-013FT5742-4B3D8HLA-ERIgG2a943 (0+)00000
G-I1TFL-185FA5850-1E1E6HLA-EGIgG119,644 (19+)00000
2TFL-184FA5850-1E1C2HLA-EGIgG119,227 (19)00000
3TFL-186FA5850-1E1C3HLA-EGIgG119,075 (19)00000
4TFL-226FA5850-9C3B4HLA-EG HLA-ERIgG118,865 (18+)
18,979 (18+)		00000
5TFL-254FA5850-14C7F1HLA-EG HLA-ERIgG11604 (1+) 1972 (1+)00000
For HLA-A, HLA-B, and HLA-C LABScreen beatsets were tested, which carry both intact HLA (closed conformers) β2m-free heavy chain of HLA (open conformers). For HLA-E, HLA-F, and HLA-G fresh beads coated with β2m-free heavy chains (open conformers) were tested.
Table
Table 3. HLA-Ib specific mAbs are non-reactive to HLA-Ia molecules.
Table 3. HLA-Ib specific mAbs are non-reactive to HLA-Ia molecules.
GroupsSubgroupsNumber of mAbsmAb NomenclatureHybridoma IDAntigen (Heavy Chain only) Tested on BeadsSubclassHLA-E Reactivity in MFIHLA-F Reactivity (MFI)HLA-G Reactivity (MFI)HLA-A Reactivity (MFI)HLA-B Reactivity (MFI)HLA-C Reactivity (MFI)
R-II 1TFL-050FT5742-12B6F3HLA-ERIgG2b4876 (4+)3292 (3)2683 (2+)000
G-II 1TFL-209FA5850-5C4F3HLA-EG
HLA-ER		IgG121,532 (21+)
21,452 (21)		8744 (8+)20,303 (20)000
2TFL-208FA5850-5C4E2HLA-EG
HLA-ER		IgG121,294 (21)
21,030 (21)		8605 (8+)20,562 (20+)000
3TFL-223FA5850-8D3A4HLA-EG
HLA-ER		IgG118,447 (18)
21,086 (21)		8587 (8+)20,587 (20+)000
4TFL-164FT5765-1C1B6HLA-EGIgG2b15,370 (15)8230 (8)24,765 (24+)000
5TFL-165FT5765-1C1G5HLA-EGIgG2b15,192 (15)8254 (8)25,812 (25+)000
6TFL-162FT5765-1C1B4HLA-EGIgG2b14,667 (14+)9015 (9)25,085 (25)000
7TFL-161FT5765-1C1B1HLA-EGIgG2b14,444 (14)8607 (8+)24,714 (24+)000
G-III 1TFL-228FA5850-9C3B3HLA-EGIgG119,581 (19+)
19,919 (19+)		1134 (1)0000
G-IV 1TFL-191FA5850-2C8C10HLA-EGNK1000 (1)01016 (1)000
Note: HLA-A, HLA-B, and HLA-C LABScreen beatsets were tested, which carry both intact HLA (closed conformers) and (open conformers). NK: not known; for HLA-E, HLA-F, and HLA-G, fresh beads coated with β2m-free heavy chains (open conformers) were tested.
Table
Table 4. HLA-ER mAbs: HLA-F, HLA-G, and HLA-A non-reactive but reactive to HLA-B and HLA-C alleles.
Table 4. HLA-ER mAbs: HLA-F, HLA-G, and HLA-A non-reactive but reactive to HLA-B and HLA-C alleles.
MFI Expressed in Thousands
GroupsSubgroupsnumber of mAbsmAb NomenclatureSubclassHLA-E Reactivity (MFI)HLA-F Reactivity (MFI)HLA-G Reactivity (MFI)HLA-A Reactivity (MFI) HLA-B Reactivity HLA-C Reactivity
B*0801B*1301B*1302B*1401B*1501B*1502B*1511B*1512B*1513B*1516B*3501B*3701B*4006B*4601B*5701B*5703B*5801C*0202C.*0401C*0501C*0602C*0702C*0801C*1802
R-III 1TFL-114 IgG2a14+ 1
R-IV[A]1TFL-004IgG2a17+ 1 1
2TFL-005IgG2a17 1 1
3TFL-019IgG113+ 1+ 1+
4TFL-020IgG112+ 1 1+
5TFL-099 IgG2a14 1+ 1+
6TFL-108 IgG2a11 1 1
7TFL-128 IgG313 1 1
8TFL-146 IgG113 1 1
9TFL-084IgG2a16 2 1+
10TFL-028IgG112+ 2 2
[B]11TFL-116 IgG18+ 1+ 1 2
12TFL-156 IgG112+ 2 1 2+
13TFL-029IgG113+ 2+ 1 2+
14TFL-030IgG2a15 2+ 1 2+
15TFL-060IgG2a18+ 2+ 1 3
16TFL-154 IgG2b19+ 3 1 3
[C]17TFL-158 IgG2b19 1 4 1+ 16
18TFL-059IgG2a19+ 1 1 3+ 1+ 4
19TFL-079IgG111+ 1 3+ 1 1+ 14
20TFL-093IgG113+ 1+ 1 1 1
21TFL-143 IgG2b20+ 1 1 4+ 1 1 5
[D]22TFL-090IgG112 1 3 1 2 14
23TFL-052IgG2b10+ 1+ 1 2+ 1 1+ 13+
24TFL-062IgG115 1 1 3+ 1 2 14
25TFL-076IgG2b20+ 1 1 4 1 1+ 14+
26TFL-076IgG2b20+ 1 1 4 1 1+ 14+
27TFL-091IgG116+ 1 1 4 1 1+ 15
28TFL-159IgG2b19+ 1+ 1 5 1 21 1+7
[E]29TFL-155 IgG2b19 8+7+ 99+174+1516+ 2+16+6+8 3
30TFL-094IgG2b18+ 12+8 910+18516+17+ 21768 2+
HLA-EG107 not tested.
Table
Table 5. HLA-ER mAbs: HLA-F and HLA-G non-reactive but reactive to HLA-A*1101, HLA-B, and HLA-C alleles.
Table 5. HLA-ER mAbs: HLA-F and HLA-G non-reactive but reactive to HLA-A*1101, HLA-B, and HLA-C alleles.
MFI expressed in Thousands
GroupsSubgroupsnumber of mAbsmAb NomenclatureSubclassHLA-E Reactivity (MFI)HLA-F Reactivity (MFI)HLA-G Reactivity (MFI)HLA-A*1101 Reactivity (MFI) HLA-B Reactivity HLA-C Reactivity
B*1301B*1302B*1401B*1501B*1502B*1511B*1512B*1513B*1516B*1801B*3501B*3701B*3901B*4001B*4002B*4006B*4101B*4403B*4501B*4601B*4701B*5301B*5401B*5701B*5703B*5801B*7801B*8201C*0202C*0303C*0304C*0501C*0602C*0801C*1402C*1502C*1601C*1701C*1802
R-V[A]1TFL-035IgG111 1 1 1 3+ 1 2 1+ 4+
2TFL-064IgG2b21 1 1 1 4+ 1 1 4
3TFL-134 IgG115+ 1 1+ 1 4 1 1+ 1 5
4TFL-075IgG116 1 1+ 1 4+ 1 2 1 5
5TFL-011IgG2a17 1 1 1+ 4 1 2 1 1
6TFL-061IgG115 1 1+ 1+ 4+ 1+ 2+ 1+ 5
7TFL-077IgG2b21+ 1 1+ 1+ 6 1+ 2+ 1 6
[B]8TFL-036IgG111+ 1 1 1 4 1 1 2 1+ 4+
9TFL-078IgG112+ 1 1 1 4 1 1 2+ 1+ 5
10TFL-096 IgG112+ 1 1+ 1 3+ 1 1 2 1+ 4
11TFL-012IgG2a17+ 1 1 1+ 4+ 1 1+ 2 1+ 4+
12TFL-045IgG2a16+ 1+ 1 1 5 1 1+ 2+ 1+ 5
13TFL-160 IgG315+ 1+ 1+ 1+ 5+ 1 1+ 2 1 5+
14TFL-105 IgG2a19 1 2 1+ 5 1 1+ 2+ 1+ 5+
15TFL-120 IgG116 1+ 2 2 5+ 1 1+ 2+ 1+ 6
16TFL-087IgG2b21+ 1+ 2 2 6 1 1+ 3+ 2 7+
[C]17TFL-106 IgG2a19 1+ 2 2 5+ 11 1 2 3 2 6
18TFL-032IgG2b21+ 1+ 2+ 2 6 11 1 2 3+ 2 7
19TFL-068IgG2a20+ 1+ 2+ 2 6+ 11 1 2 3+ 2 7+
20TFL-088IgG2b21+ 1+ 2+ 2 7 11 1+ 2 4 2+ 8+
21TFL-065IgG118 2 3 2+ 7 11 1+ 2 3+ 2 8
22TFL-149 IgG2b22 2+ 3 2+ 18 11 1+ 2+ 3+ 2+ 4
23TFL-150 IgG2b22+ 2 2+ 2+ 17+ 11 1+ 2 3 2 8
24TFL-066IgG116+ 2 3 2+ 17+ 11+ 1+ 2+ 4 2+ 8+
25TFL-067IgG2a20 1+ 2+ 2 6+7 11 1 2 3+ 2 7+
[D]26TFL-130 IgG116 1+ 2+ 1 1 2 5+ 1 1 2 2+ 1+ 6+
27TFL-117 IgG2b22 2 3 1 1 2+ 18 11 1+ 2+ 3+ 2 8+
28TFL-151 IgG116+ 1+ 2+ 2 5+ 1 1 1+ 2+1+2 6+
29TFL-136 IgG2b20 1 2 1+1 6 1 1 31+2 8+
30TFL-135 IgG116 2 3 2 16 11+ 1+ 2 31+2+ 11 7
31TFL-152 IgG2b20 1 2 1+1 6 1 1 322 11 8+
32TFL-100 IgG116+ 2+ 2+ 13 1 17+ 11+ 2 2+ 3+ 2+ 7
33TFL-140 IgG2b22+ 2+ 3+ 13 18+ 11+ 1+ 3 4+ 2+ 9+
34TFL-139 IgG2b22+ 3 3+ 13+ 1 19 11+ 2 3 4+ 3 10
35TFL-124 IgG116 2+ 3 12+ 16+111+ 1+ 2+ 3+22+ 11 7+
36TFL-009IgG2a17+ 2 2 1 12+ 1 1611+1+ 1+ 2+ 1 4 2+ 7+
37TFL-053IgG2a20 2 3 12+ 1 17+11+1+ 1+ 2+ 4 2+ 8
38TFL-054IgG2a20+ 2 3+ 13 1 17+11+1+ 1+ 2+ 4+ 3 8
39TFL-089IgG2a20+ 2 3 12+ 1 17+11+1+ 2 2+ 4+ 3 8+
40TFL-115IgG2a19 2 3 12+ 1 1711+1+ 1+ 2+ 4 2+ 8
[E]41TFL-121 IgG120+ 2+ 3 11 1 13 18 11+ 1+ 2+ 4 2+ 8+
42TFL-002IgG2a19+ 2+ 2+ 11 13 1 1711+2 2 31 4 2+ 7+
43TFL-003IgG2a19 2+ 2+ 1 13 1 17+11+2 2 31 4 3 7+
44TFL-021IgG118 3 4 11 13+ 1 1+8+11+2 2+1 31 5 3+ 9
45TFL-022IgG118 3 4 11 13 1 1811+2 2 31 4+ 3 8+
46TFL-023IgG2a21 2+ 3+ 11 13 1 18+11+2 21 31 5 3+ 9
47TFL-024IgG2a20+ 2+ 4 11 13 1 1811+2 2 31 5 3 0
48TFL-031IgG118+ 3 3 11 14 1 1911+2 2+ 3+1 5 3 9+
49TFL-123 IgG116+ 2+ 3 1 13 1 1711+1+ 2 31 4 3 8
50TFL-122 IgG117 3 3+ 1 13 1 17+11+3 2 31 4 3 8+
51TFL-131 IgG2a20+ 3 4 11 1 13+ 111+7+1+22 2+1 3+1 1 5 3 8
52TFL-132 IgG2a20 2+ 3+ 11 13 1 16+11+1+ 21 31 4+ 3 7+
[F]53TFL-138 IgG2a22 31 4 1+2+ 21+14 1 1+9+11+21 2+ 3+1 5 3+ 10+
54TFL-083IgG117+ 2+1+ 4 24+ 3+313+ 1 1811+22+ 2 31 4+ 3 9
55TFL-157 IgG116 2+1 3 1+3+ 2+213 1 17111+1+ 2 2+ 3+ 2+ 7+
56TFL-092IgG117+ 2+1+ 3+ 24+ 3+2+1311 17+111+2 2 2+ 4 2+ 8
57TFL-127 IgG116+ 31+ 3+ 24+ 3+313+ 1 1+7+11+22+ 21 31 4+ 3 8+
58TFL-137 IgG2b22 3+1 4+ 1+3 2+214 1 1+9+11+21+ 2+1 3+1 5 3+ 10+
59TFL-040IgG2a19 3+1 3+ 11 1+4 1+ 1+8+1+22+1 31 4111 5 3+ 9
60TFL-080IgG114 2+ 5 11+ 1 23+11+11+81+22+112+1 3111116 4+1 10
61TFL-026IgG117+ 3 4 11+ 1 1+3 1+11+7+1+22+112+1 31 11 5 3+1 18
[G]62TFL-119 IgG2a18+ 1+5+52+76+12+3+11+9+ 2 5+ 119+ 1 3+5+2 3 2 7
63TFL-142 IgG2b22+ 39+8+4+10+1117+615+1513+ 1 1911+213+ 2 793+1 5 3+ 10
64TFL-153 IgG2b22 2+108+410+111861614+13+ 1 1811+1+14 2 7931 5 3 10
65TFL-118 IgG2a20+ 3+10+10512+12+20817+17+1+4 1+ 1+912216 2+18+10+3+1 1 5+ 3+ 10+
66TFL-133 IgG2a22 3+11+10+512+1320+817+17+1+4+ 1+11+101+22+16 31910+41 1 6 4 11
67TFL-141 IgG2b22+ 3+11+115+1313+21818+181+4+ 1+11+10+1+22+17 31911+41 1 6+ 4 12
68TFL-095IgG2b22+ 4+1313+6+1716+241221+20+25121211+1+2+321 3+11213+51+11 7+ 5 13
Table
Table 6. Evolving HLA-ER mAbs: HLA-F, HLA-G non-reactive but reactive to HLA-A, HLA-B, and HLA-C alleles.
Table 6. Evolving HLA-ER mAbs: HLA-F, HLA-G non-reactive but reactive to HLA-A, HLA-B, and HLA-C alleles.
MFI Expressed in Thousands
GroupsR-VI
Subgroups[A][B][C][E][F]
Number of mAbs1234567891011121314151617181920212223242526272829
mAb NomenclatureTFL-015TFL-027TFL-039TFL-111 TFL-010TFL-014TFL-082TFL-102 TFL-101 TFL-072TFL-086TFL-113 TFL-085TFL-008TFL-038TFL-057TFL-098 TFL-025TFL-112 TFL-037TFL-071TFL-097 TFL-048TFL-058TFL-017TFL-018TFL-070TFL-051TFL-069
SubclassIgG2aIgG1IgG2aIgG2aIgG1IgG2aIgG2aIgG2bIgG2bNTIgG3IgG2bIgG3IgG1IgG2bIgG1IgG1IgG1IgG2bIgG2bIgG2bIgG2aIgG1IgG1IgG1IgG1IgG2bIgG2bIgG2b
HLA-E Reactivity 19+17+2018+18+19+18+2221+15+17161619241717+17232423+2117+17+17+17+2323+22+
HLA-F Reactivity
HLA-G Reactivity
HLA-A Reactivity A*11013+3+43+444553434+5+6+3+4+5+778744+4+4+8+8+9
A*2402 11 1+21+11+2 111222
A*2403 11+1111+ 1111+1+1+
A*2601 1 11
A*2901 11111 11+11+211+1+1+222
A*3001 1
A*3002 1 1111+1+1+
A*3201 111 1111+1+1+
A*3301 1 1111111+1+
A*3303111111111111+1+1+1+1+11+222+3222+23+3+3+
A*3401 111111111+ 11+1+1+222222+2+3
A*3601 111 1 111111111+1+22+11+1+1+2+2+3
A*4301 1 11111+1+
A*6601 1
A*6802 11 1
A*8001 111
HLA-C Reactivity C*0102 2+ 1 1 121+1+1+11+1+
C*02021+1+1111+ 111+22+21+2+3122+2+334+3+3+3+444+
C*0302 211+1112 1111+1+322+2222+
C*030311 111 1+1+21+1+1+2+11+2+22+33+3333+3+4
C*0304 1 1 1+1+1+11+2+111+1+22+3332+333+
C*0401 1 1+111 1
C*05015+5+5+55+5+6776+66+6+7+9+767+101010+99+87+7+111111+
C*0602 1 1+1 11+ 1111+522+2222
C*0702 1 1 1 13+1+1+1+111+
C*08013+443+44454+554+55+764+67+7+87+776699+9+
C*1203 2 1 1211+1+111
C*1402111111111 1+21+1+1+2+11+222343333+3+4
C*1502 111+1111+ 11+1+1+22+22+22+2+2+
C*160111 1+1 111+1 11+ 11111+3222222
C*1701 1 1 1+11+1112 1111+23+2+2+2+2+2+2+
C*18028+8+9+8+109911+11+9+9+9+9+11+1510+1011+14+1515+1312121110+15+1615+
HLA-B Reactivity B*0801 1+ 1
B*130111111111111+21+1+31+1+1+2+3+2+3+22+2+2+3+3+4
B*1302 11 1+ 1111+111+1+
B*14013+4+43+53+44+55+5+5+668+656+8+998+887710+10+11
B*1402 1111 11+ 1111+22+22+22+2+2+
B*150211+111+1+1+1+1+222224+2+22+353+433334+4+5
B*1503 1 1 1111+1+1+1+1+222
B*1510 11111111
B*1511 1+1+1+1+1+1+1+1+1+222+22+52+22+3+5+3+43+3+3+3+4+55
B*1512 1111111
B*15131111111111+1+21+1+4211+24+2+2+2+2+2+2+3+3+3+
B*1516 1 111 111+1+131+11+23+22+222+2333
B*18011+1+1+1+1+22222+2+332+3+3234444+43+43+55+5+
B*2705 11111111
B*2708 1 1111 11+ 1111+221+22222+
B*3501444+44+44+5+5+3+4+455+7+4+56888+7+5+5+5+5999+
B*3701 1 1 222+21+02+122+32+3+ 343+444+
B*3801 1 11 1
B*39011+1+21+21+22222+2+2+2+3+2+23444+4+3+3+3+3+5+4+6
B*400111‘1111111+1+221+221+22+2+2+32+3333+3+4
B*40021+1+2222222+22+22+2+3+2+23444433+3+3555+
B*4006889+8+98+911+11+8989+11149911141414+12+1010+9+9+14+14+15+
B*41011+1+21+222222+2+2+2+2+3322+43+44+3+3+3+3+555+
B*4402 1 1111111+ 11+11+2222+22+2+2+
B*44032+2+2+22+2+2+2+2+232+33+43+2+3+4+4554444666
B*45012+332+3333+3+343+44+543+4+6+5+6+655557+7+8
B*46011111111111+1+21+1+3+211+2+3+2+32+2+2+2+33+3+
B*47011111111 1+1+21+1+1+2+11+222+333333+3+3+
B*4801 111+1 11+ 1111+2222222
B*5101 111111+1+ 11+1+1+222222+2+2+
B*5102 11 111111+1+11+2222+2222333+
B*5201 111+1111+ 11+1+1+22+2+2+22+2+2+
B*530122+333234433+3+44+5+3+3+4+6+66+6+4+4+54+7+7+8
B*54011+1+1+1+1+1+1+1+1+1+22222+222+3+33+433334+4+5
B*5501 11 1111 1 11+ 1+1+21+222+
B*58013+3+43+44455 43+4+5+74+4+5+77+7+7+4+5558+99+
B*5901 111 11+ 11111+2222222+
B*7301 3 11 11 1111+1+1+1+1+222
B*78011+1+1+1+1+1+1+2212222+3222+3+33+433334+54
B*8101 1+ 1
B*82011111111111+1+1+1+1+2211+2+22+332+32+3+3+3+
Note: For HLA-E only HLA-EE107 was tested for MFI.
Table
Table 7. HLA-EG mAbs: HLA-F, HLA-G, and HLA-A non-reactive (G-II) or reactive only to HLA-A*1101, and to both HLA-B and HLA-C alleles.
Table 7. HLA-EG mAbs: HLA-F, HLA-G, and HLA-A non-reactive (G-II) or reactive only to HLA-A*1101, and to both HLA-B and HLA-C alleles.
MFI Expressed in Thousands
GroupsSubgroupsnumber of mAbsmAb NomenclatureIgG SubclassHLA-ER Reactivity (MFI)HLA-EG Reactivity (MFI)HLA-F Reactivity (MFI)HLA-G Reactivity (MFI)HLA-A*1101 Reactivity (MFI) HLA-B ReactivityHLA-C Reactivity
B*0702B*0801B*1301B*1302B*1402B*1501B*1510B*1511B*1512B*1513B*1516B*2708B*3501B*3901B*4001B*4002B*4201B*4402B*4501B*5001B*5201B*5301B*5401B*5601B*5701B*5703B*5801B*8101C*0401C*0702C*1402C*1701C*1802
G-V 1TFL-175IgG1 12 1+ 1+
2TFL-174IgG1 12 1+ 1+ 1
3TFL-173IgG1 12 1+ 1+ 1
4TFL-219IgG12120+ 2 2 1
G-VI[A]1TFL-222IgG11918+ 1 3+ 2 1+1
2TFL-220IgG11919+ 1 3+ 2 1+1
3TFL-187IgG2a2524+ 1+ 3+ 2 1+1
[B]4TFL-201IgG11112 1+ 1 3 1+ 2+1+ 3
5TFL-193IgG11415+ 2 11 5 2+ 3+2+141
6TFL-194IgG12121 2 11+ 5+ 3 3+314+1
7TFL-199IgG115+15+ 2 11+ 4+ 2+ 3+2+141
8TFL-258IgG120+20+ 3+ 01 7 1 1 4+ 43 1
9TFL-257IgG120+21+ 3+ 11 7 1 1 4 43 51
[C]10TFL-253IgG2b26+26 6 12+2+ 1 111 11 2 1+12 7+11 7+1+175+1+8+2
11TFL-249IgG2b26+25 6 12+2+ 1 111 11 221+12 7+11117+1+175+1+92
12TFL-250IgG2b2726 6 12+2+ 1 10+1 2 1+12 7+11 17+1175+1+8+2
13TFL-241IgG12221 4 2+13+238+1+7+1412 1+ 1 11415 5+115 4+4163+
14TFL-242IgG12221+ 4+ 2+1423+91+7+1412+ 11+ 1 1+14+151 5+115 54164
15TFL-247IgG121+20+ 4 2+14238+1+7+14+12+ 1+ 1 14+151 5+11+51 4+ 164
Table
Table 8. Evolving HLA-EG mAbs: HLA-F and HLA-G non-reactive but reactive to HLA-A, HLA-B, and HLA-C alleles.
Table 8. Evolving HLA-EG mAbs: HLA-F and HLA-G non-reactive but reactive to HLA-A, HLA-B, and HLA-C alleles.
GroupsG-VII
MFI Expressed in Thousands
Subgroups[A][B][C][D][E][F][G]
Number of mAbs12345678910111213141516171819202122232425
mAb NomenclatureTFL-221TFL-218TFL-217TFL-216TFL-196TFL-167TFL-231TFL-252TFL-170TFL-169TFL-166TFL-168TFL-251TFL-207TFL-206TFL-205TFL-243TFL-246TFL-244TFL-245TFL-189TFL-190TFL-188TFL-172TFL-171
IgG SubclassNTIgG1IgG1IgG1IgG2aIgG1IgG2bIgG2bIgG1IgG1IgG1IgG1IgG2bIgG1IgG1IgG1IgG2aIgG2aIgG2aIgG2aIgG1IgG1IgG1IgG1IgG1
HLA-ER Reactivity 2521202024 24+25 2618+19 2624+252513+14+14
HLA-EG Reactivity 252019+20241524251717+16+1525+17+1918+2524+24+24+15+16+1614+15
HLA-F Reactivity
HLA-G Reactivity
HLA-A Reactivity A*0101 1415
A*0201 11
A*0203 1+1+
A*0206 111111111+ 1+1+
A*0301 12+14
A*1101655+5+45+8+9+6+6+6+6+9+888121212121+1+1+9+10
A*1102 1110+11+11 1111+
A*2402111111+2+3222233332+2+33 11
A*2403 11111111+1+1+
A*2601 11+21+22222+333 11
A*2901 111+1+1+1+1+1+222
A*3001 1111111+1+1+
A*3002 11111111+222
A*3201 11111111+1+1+1+
A*3301 11111111+1+1+
A*3303 111+1+1+1+1+1+222 14+15
A*3401 1111 1112
A*3402 111 11+12
A*3601 11 1111+1+1+ 1112
A*4301 111 11+12+
A*7401 1+1+1111+1+1+1+ 1+22+13+14
A*8001 33+
HLA-B ReactivityB*0702 111
B*080115+3331+2+2343333420+19201+1+1+1+ 1111+
B*130116+1717+17+242464+4+4+4+620+19+203333<11122+
B*1302333323+66+4+4+4+4+76668988+<1<1122+
B*1401 11+11111+2227+77+8
B*140247+88+ 11 12+12+12+
B*150110+12+12+131217+3+2+2+2+33+16+16+16+6666+ 11
B*1502 1111111+1+1+15+1515+15+ 1213
B*1503 11 11+1+1+109+1010+
B*15101+44+5 5+ 87+8 1+1+
B*151110+8+98+6+813+1499991411+10+1110+10+101044+4+11+12
B*151217+17+17+1812+23+3+33333+202019+8+7+8+9 11
B*151312+15+16+17 1221111112018+197+788+ 14+15+
B*15161+1+1+1+1233+2+2+2+2+3+3+3+3+11+1+1+ 11
B*1801 11
B*2705 1111
B*2708111+1+122+3+2+2+2+2+3+3+33+1111 1
B*350111+1+1+123+432+3344441+11+1+ 1314+
B*37010000 111
B*39012+22+2+1+34+5+3+3+3+3+5+5552+2+2+2+ 1112+
B*40011111 1+22+22222+3331111 77+
B*400221+221+2+45+3+33+3+54+4+4+2+2+2+2+ 99+
B*4006 111+1+1+1+1+1+222
B*42011+11+1+12342+2+2+2+444432+33 12+13+
B*44022+2221+34+5+3+3+3+3+5+554+2+2+2+2+ 8+9
B*44030000 1111111+1+1+ 66
B*450116+1818+18+ 1+23+221+222202020+ 13+15
B*4601 111+11111+222 10+11+
B*4701 11111111+1+1+ 1214
B*4801 3+2+3+4 99+
B*4901 4+455 8+9+
B*500111+1+1+123+42+2+2+2+44446+5+6+7 11
B*5101 111+11111+2225455+
B*5102 1111111+1+1+23+344 1112
B*5201766+6+4+6+10+117+7+77+119+9+9+6+76+722+2+4+5
B*5301111+1+1223+2+2+2+2+3+3331111+ 11
B*5401111111+2+3+22223+333+15+15+1515 11
B*5501 9+ 111+11111+1+1+1+0000
B*5601799+1511+12+2+2+22+2+31312+12+<1111 22
B*57011314+14+6+12+2043333417+17+181111 4+5
B*57037+6+6+24+610+10+777710+989776+72+32+77+
B*58011+1+2112+44+33334+4+4+ 1+1+1+1+2+3311+
B*67011111+11+22+22222+333 1
B*7301 11+2+1+1+1+1+2+2+2+2+12+121213
B*7801 00000000 1110000
B*8101111+012342+2+2+2+43+3+3+1+1+1+1+ 11
B*8201 1121+1+1+1+2+222 1213131416
HLA-C ReactivityC*0102 1 111111+1+1+1+ 10+11+11+1415+
C*0202 1+12+1+1+1+1+2+2+2+2+13+11+13+13+13+13+14+13+15
C*0302 1111111+1+1+86+8+816+16+16+1415+
C*030311161223+2+2+2+2+3+3+33+97+991515151415+
C*0304 1121+1+1+1+2222 5+6+6+13+15
C*04016+5+65+4+6910+776+710+8+8+86+6+6+6+1011+111314
C*0501 1121+1+1+1+221+211112020191314+
C*0602 111+11111+1+1+1+11+10121217+17+181214
C*07025+5+5+1 9+6+6+6+6+9+87+7+5+5+5+5+1112+12+13+15
C*0801 1111111+11 2020+2015+17
C*1203 11211+1+3222232+2+2+11111313+1413+14+
C*14021+1+27+1+2+3+4+33334+43+419+19+19+19+18+18+1814+16
C*1502 1121111221+224+24+24+24+18+1918+13+15
C*1601 111121+1+1+1+2+2+2+2+2221+21+21+1616+171314+
C*17018+77+4+5724+12888812109+9+888811+12+12+14+16
C*1802184+4+01+3+ 5+4444+620+2020+2+2+2+2+1111314+
Table
Table 9. Evolving HLA-ER and HLA-EG mAbs: HLA-Ib mAbs also react to all HLA-Ia isoform alleles.
Table 9. Evolving HLA-ER and HLA-EG mAbs: HLA-Ib mAbs also react to all HLA-Ia isoform alleles.
GroupsR-VIIR-VIIIR-IXR-XG-VIIIG-IXG-X
MFI Expressed in Thousands
Subgroups [A][B][C][A][B]
Number of mAbs11211212345678910123456789101112131415161234
mAb NomenclatureTFL-063TFL-103TFL-104TFL-049TFL-006TFL-007TFL-227TFL-197TFL-198TFL-202TFL-203TFL-204TFL-210TFL-211TFL-212TFL-235TFL-230TFL-256TFL-224TFL-214TFL-213TFL-215TFL-225TFL-233TFL-240TFL-238TFL-236TFL-237TFL-239TFL-234TFL-248TFL-229TFL-232TFL-177TFL-176TFL-198
IgG SubclassIgG2bIgG1IgG1IgG2bIgG2aIgG2aIgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG3IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG1IgG2bIgG3IgG1IgG1IgG1
HLA-ER Reactivity 22+1817+1522+21+181716181817+19181821022+2220+21211919+1818192019+1921+3022+14+13+15
HLA-EG Reactivity 18+161517+16+16+17+17+1819+18+2220+21+2020+19+18 19+19+182127+21
HLA-F Reactivity 3+ 8+12+115+10+101110+10+1111119 2+54+10
HLA-G Reactivity 4+4+7+7+2+ 11122+2+11+11+1413+9+810218+21+11110+
HLA-A ReactivityA*0101 215+ 13 11 14000
A*0201 3
A*0203 1 2+22+2+2+2224+ 2
A*0206 1 3+2+3+3+3+3334+ 002+
A*0301 375+8+553+33+10 5+
A*110126611084111011+11+1111+1111114+4+4+555+5+5+5+55+76+77+9+ 3+410
A*1102 3111+111119 1
A*2301 3+9+8111010+10101011 8
A*2402 2+3 324+14+1315+14+14+141414+12+11+111+1+11 2+2+31+2+ 1+1+13
A*2403 2+2+ 31+4+12+1113+13+1313+12+1312 111+ 1 1111
A*2501 1 4
A*2601 31+ 111+111118 22+2+2+22+1+2 221
A*2901 1+1+ 32 54+6+554+44+6+ 11111 11+4+
A*2902 21 6+57+65+4+44+6 005
A*3001 215546+4+4+43+412 1+11+ 114
A*3002 11 3237686+6+6+66+9+ 111 1 6
A*3101 43533+2+223 3
A*3201 11 21+ 3+2+4+332+2+2+5 111 1 12+
A*3301 11 2+1+ 6+5+7+6+6+5+55+5+ 111 1 115+
A*3303 22 42+1+76+877+7+7+7+8+ 1111+11 11+6+
A*3401 1+1+ 63+ 1+11+1+1+1+1+1+3+ 1
A*3402 1 44+454+554+511+ 1014
A*3601 22 5+3+ 111111118+ 1111 1 111
A*4301 1 42 5
A*6601 3+1+ 6+5+7+6+6+5+554+ 5+
A*6602 1 3+34+3+3+3332+ 3
A*6801 1 5+4+6+5+5+544+5 4+
A*6802 11 21 21+2221+1+1+8 1+21+
A*6901 1+ 6+57+5+53+3+44+ 5
A*7401 12+22+2+2+2+22+10 111+ 1 112
A*8001 2+12131313+13131312+12+9 13
HLA-B ReactivityB*0702 1 4+1817+18+181817+171813+ 21+2 17+
B*0801 2172+232+2+2+2+2+15111111+1+1+22219+19+19+2+24+1+222
B*1301 22+ 5+3+8+18+1919_1918+18+1818+162222+2+2+2+2+3+331920+19+4+243+3+418
B*1302 1 21613+12+14+13+1413+13+13+13+2222+2+2+2+3333+6663+6+ 2+2+12+
B*14012772118+615+14+161615+161615+14 32+3 1+ 114+
B*1402 1+1+ 42+29+8101010+9+99+8+ 12+12+12+ 11+ 8
B*1501 1 45+4+65+65+5+5+11+ 1111111111161616218+ 1+24+
B*1502 33 646+1918+19+19+19191818+15 11+1+2+22+ 581118+
B*1503 11 2+1+6+16+16+17+17+171716+18+14 1+1+1+ 1 1116+
B*1510 2+11878+887+7+7+6+ 87+8 5 7
B*1511 33+ 95+91514+1615+15+15+1515+16+7+7+88+8+999999+10+1010+10+1616714+
B*1512 1+ 73+34+443+33+15111111111+1+1+91919+2242+22+3
B*1513 22 536+1+11+1+1+1+1+1+15 1919+18+ 22+4111
B*1516 22 5+34+1513+15+15+151514+14+12111111111123332+3 1+213+
B*1801 3+3+ 6+4+210+1011+1110+10+10+10+7+ 10
B*2705 2+1+18+7+8+8+8+87+86+ 7+
B*2708 11 42+4+5+4+65+5+5+55+11+ 1 111111112+22+22+ 224+
B*350126+6+1108+7+19192019+18+18181816 1 11+11133+3+8+892+892219
B*3701 2+3 64615+15161616+15+15+15+14 111 1115
B*3801 3+1+3+13+12+1413+13+1312+13+11 2233344445 12+
B*3901 3+3+ 757+19+1920+2019+19+18+1915+1+21+22+2 2+319
B*4001 2+2+ 5+3+4+15+1516+1615+161515+12+ 11 11121+222 1115
B*4002 3+3+ 64+643+4+44+444141+1+1+1+1+221+222+333+3+4 22+3+
B*400671111315+13+ 4+3+5+4+4+43+43+ 11111 13+
B*4101 3+3+ 75315+1515+15+15+15151510+ 15
B*4201 39+8+1110109+9914+11111+1+112+2+33+3+3+2+9+12+2+38+
B*4402 1+1+ 741+6+67+77666101+1+1+222222223+3+3+3+4+ 22+6
B*4403 44 75+3+ 1 1 11 1
B*4501155+ 9+7+6+191920+19+1919191916 1 19+21201+2522219
B*4601 2+2+ 646+17+171917+1817+171814+ 111+1211117
B*4701 22 6+3+8+20202119+19+19191916 1+22+3+33+ 221+1+20
B*4801 11 42+7 14+
B*4901 5+ 13+
B*5001 843+4+4+4+4+44+15+111111+111+1+1+54+52+3+ 2+2+3+
B*5101 1+1+ 63+7+1+1+21+1+1_1+1+15 2+22+11 1+1+1+
B*5102 22 53+721+22222215+ 32+3+ 1 111+
B*5201 1+1+ 4+2+9+1091110+10109+1015+5+5+5+666+6+6+66+6+8+99812 5+6+9
B*530115+5+ 8+76+2+2+32+2+2+2+2+14111111111+1+1+1+1+1+22+ 1+22+
B*5401 33+ 5+452+2+3332+2+2+12+111111111+1+1+3+33+13 1+1+2+
B*5501 2+1+22+22+2+2+2228 11111 2
B*5601 1 2+4+3+4+4+4+444+10 111111112+12+12+213+ 113+
B*5701 55+4+65+5+5+5+5+13111111+111+1+1+17+1817+2+21+ 224+
B*5703 1 712+11+1312+12+12+12+12+13+55+5+666+6+66+66+88+8812+155+11+
B*5801266+110892+22+2+2+2+2+2171111+1+1+1+1+2+2+2+65+62+512+32
B*5901 11 5+3298109+9+9998+ 8
B*6701 4+4+454+4+4+4+4+11 22222 11+4
B*7301 11 326+43+44443+414 1113331+2 1+1+3+
B*7801 33+ 64+518+17+1918+18+17+17+1813+ 111 17+
B*8101 1 7+19+19+20+19+19+18+19+18+161 111+1+1122+2+4+4+52+5+42219+
B*8201 32+ 4313201920+2019+19+19+19+18+ 1+1+1+1111+2+333+19
HLA-C ReactivityCw*0102 7311+202920+20+20201919+18+ 11 12222+19
Cw*0202 2+2+ 10+61115+1416+15+15+1110+1116 11111111+ 2214
Cw*0302 1+1+ 5+310 15+ 1+2
Cw*0303 22+ 749+7+6+8+87+76+715+ 111111+1+1+1+1+1+22+ 2+36+
Cw*0304 22 6+3+1121+2+2+2+5+5517 11+1+ 1+2+3+1+21+
Cw*0401 2+19+181819+19+191818+1815+555+5+666+66666+6+6+7+12+25+618
Cw*0501488+216131376+87+7+121212+18+ 2+3+3+11115+13+2+2+6+
Cw*0602 11 9416+54+65+5109+1018+ 1+22 14+9+674+
Cw*0702 126+1019+17+19+1919+18+18+19174 555+5+5+666+6+10+15+617+
CW*0801366+1+1310+1121+2022212121212119 11+1+ 2+511+20+
Cw*1203 521219+19+212019+19+191917 11 1+221+11+232+2+319+
Cw*1402 22 8+4+910+9+1110+109+9+9+16+ 1+1+2+33222+352+22+9+
Cw*1502 1+1+ 631120+20+2220+202019+19+18+1111+1+1+ 1+22 11+47+2+320+
Cw*1601 11+ 8415+19+19+2119+1918+1918+18 1 1+1+1+11122+3+6719+
Cw*1701 1+1+ 13+91113131413+141414+14+17666777+7+7+7+7+7+888915466+13
Cw*180281111+417+158+9+8+109+9+99916+1+1+2222+223+3+3+19+20+10+424+33+46+
Table
Table 10. TFL-006 fails to recognize HLA antigens coated on LIFECODES beadsets as they contain only intact HLA (closed conformers).
Table 10. TFL-006 fails to recognize HLA antigens coated on LIFECODES beadsets as they contain only intact HLA (closed conformers).
HLA-I Reactivity with TFL-006 (MFI) at 20 mG/mL *
HLA-ILABSCreen LIFECODESHLA-ILABSCreen LIFECODES
(Lot # 10)(Lot # 11)3005613(Lot # 10)(Lot # 11)3005613
A*01:019338520B*07:028626700
A*02:013395420B*08:01122612040
A*02:0310181560B*13:01n/a675
A*02:06n/a616 B*13:02251449230
A*03:011932100B*14:01780519830
A*11:01478239000B*14:0218311970
A*11:025373210B*15:0133525410
A*23:011331250B*15:0219358090
A*24:027165800B*15:03182211460
A*24:03251610420B*15:10n/a579
A*25:011943490B*15:11n/a1658
A*26:01222122730B*15:1277018750
A*29:01101716670B*15:13313524370
A*29:027787150B*15:1630768820
A*30:01149612430B*18:01309628910
A*30:02n/a728 B*27:0563432520
A*31:013966870B*27:08165920950
A*32:015153410B*35:0161285170
A*33:0110385740B*37:01265043520
A*33:0355410390B*38:01252124250
A*34:01n/a3002 B*39:0170444470
A*34:02153511650B*40:0134293300
A*36:0113539410B*40:02269733540
A*43:01247927680B*40:06n/a1869
A*66:01188621450B*41:01373913640
A*66:02145413270B*42:013479570
A*68:017134540B*44:0236508920
A*68:0211855780B*44:03182925160
A*69:01312817860B*45:01173625680
A*74:016526030B*46:01357214150
A*80:01313237580B*47:01215218590
B*48:01326224180
B*49:01155430420
0B*50:01179942460
C*01:02406628200B*51:01246124130
C*02:0274463403 B*51:02n/a696
C*03:02n/a66140B*52:01214617450
C*03:03245830710B*53:0154426950
C*03:04450481670B*54:01166224270
C*04:01333741820B*55:01251948670
C*05:01912425670B*56:01366230840
C*06:02564457940B*57:0120891410
C*07:02870216890B*57:03n/a1878
C*08:0160904479 B*58:01526831900
C*12:03n/a67310B*59:01355312780
C*14:02393736270B*67:0140635200
C*15:02446546510B*73:01142335650
C*16:01464827060B*78:01299652710
C*17:01829657600B*81:01152524460
C*18:02n/a829 B*82:02n/a1959
Note: TFL-006 binds to LABScreen beadsets, wherein β2-m-free HLA HCs (open conformers) that are admixed with intact HLA (closed conformers). Alleles in bold are antigens unique to LABScreen, * MFI less than 30 are indicated as 0.
Table
Table 11. HLA-Ia reactivity of antibodies of non-alloimmunized males.
Table 11. HLA-Ia reactivity of antibodies of non-alloimmunized males.
HLA AllelesID of Non-Alloimmunized Healthy Males
Values Expressed as Mean Fluorescent Intensity (MFI)
TJ HR MERC TPCM MR TSNR VJ HO
HLA-A ReactivityA*1101 769898
A*2301 609972
A*2402 61672686963210997387841021
A*2403 557599
A*2501 906
A*2601 8356131094
A*2901 1013
A*2902 7152224
A*3001 540
A*3101 578
A*3201 5391511
A*3301 5021260
A*3303 712
A*3401 958 71018677492070
A*3601
A*4301 7795621660
A*6601 2535 1387
A*6602 1830 1382
A*6802 818 946
A*6901 628618581523
A*7401 716
A*8001 595919
HLA-B ReactivityB*1301 556 5649697377221025
B*1302 582594
B*1401 524 518704506602976830944911
B*1402 552 556648624
B*1502 618 523573
B*1503 535
B*1510 5781089
B*1511 592 634703667862111388210141268
B*1512 5621923 564 2484 501
B*1513 507745757713808
B*1516 596572 571100975013412200
B*3501 727
B*3701 748550137488111357255103120312151901
B*3801 559
B*4001 739
B*4006 746 97693257811961586128812111749
B*4402 5762027546 1375713688779
B*4403 1777
B*4501 6732044 506
B*46012821 442941 741549 558871842
B*4701 929
B*4801 697 609 648537
B*5101 626658687718
B*5102 525 656748
B*5201 8365656721281
B*5301 816693748842
B*5401 565627
B*5501 548 541604
B*5601 537 1197
B*5701
B*5703 632829
B*5801 659669 6539608859341193
B*5901 591552 658675887900
B*6701
B*7301 583
B*7801 812574680648
B*8101 807 543
B*8201 799942 32599891041994993
HLA-C ReactivityC*0102619130167614211588145116821796187617742602
C*0202680131487712861823103217582080183318242508
C*030254913977591226128088612911913189713511893
C*0303 14426079371073 9771376141711511619
C*030462014386891211139566813092017174314872209
C*04019071602129920382427111321302815261021484036
C*0501628114910781268140665918142123185115291762
C*060213262657144525203017157226753410274329452819
C*070211201649152022762748142628013562344127604098
C*0801 855 9261027 11171423127412811514
C*120355092067211871402120714301631150215901820
C*14027921609110017782045115520192669238620233444
C*1502 7015099151119108610251348112213641489
C*1601652124910641362159687715102044173120382093
C*1701720139610431719219776317352683212017921885
C*180211751878163421352386154926053014293224632695
Note: Sera were purified using protein-G column and elute-2 alone (1/10 dilution) used for monitoring the HLA-I reactivity using Luminex Single Antigen Bead Assay.
Table
Table 12. An unaltered profile of HLA-Ia reactivity in the sera of six melanoma (Stage IV) patients before and 4 weeks after administering autologous melanoma cell vaccine (tumor cells treated with IFNγ were co-cultured with autologous dendritic cells in 1:1 ratio).
Table 12. An unaltered profile of HLA-Ia reactivity in the sera of six melanoma (Stage IV) patients before and 4 weeks after administering autologous melanoma cell vaccine (tumor cells treated with IFNγ were co-cultured with autologous dendritic cells in 1:1 ratio).
Mean Fluorescent Intensity (MFI) of Anti-HLA-Ia IgG Antibodies in Melanoma Patients before and 4 Weeks after Autologus Whole Cell Cancer Vaccine
Patient IDBefore and after 4 Wks Post vaccineER*0101HLA-B ReactivityHLA-C Reactivity
B*0702B*1301B*1401B*1512B*1516B*2705B*2705B*2708B*3701B*4001B*4002B*4006B*4201B*4402B*4701B*5401B*5501B*5601B*5701B*5703B*6701B*8101B*8201C*0101C*0202C*0302C*0303C*0304C*0401C*0501C*0602C*0702C*0801C*1203C*1402C*1502C*1601C*1701C*1801
HCC-1763PreVax550 590
PostVax830 1330
HCC-1766PreVax3140
PostVax3830 700
HCC-1937PreVax3710
PostVax4040 570 940650 550 670 1107
HCC-1896PreVax37103340 14901740 1080980 1430 1150820 121032501170
PostVax45203610 17201820 9901030 1480 1190830 124034601210
HCC-2030PreVax1650 54012,3301180 540 530 8760540570 34606180540 6140750750930500 70021809501500 660 600 1830910
PostVax8620 640123012,7002240 790 760 9040830950 31905520670 5340158013401901103069013302560169029406501240 630 27301300
HCC-1957PreVax3870 540 640 1250 570 10801020 540 7701150 580 560
PostVax4990 1050 1370 2550 1170 225019337001620880 13702040 850 850
Table
Table 13. Profiles of HLA-Ia reactivity of sera of HLA-sensitized ESKD patients waiting for transplantation.
Table 13. Profiles of HLA-Ia reactivity of sera of HLA-sensitized ESKD patients waiting for transplantation.
Patient ID10DM17LE12DM20HN5DM 19HN 1DM 11DM
No of AllelesHLA-A19361021022
HLA-B11415141016124
HLA-C21100220
HLA-A ReactivityA*01:01 9470 1694125514,9613937
A*02:01 1364 1894 872
A*02:03 1034 1809 690
A*03:01 5139
A*11:01 4621
A*11:02 4519
A*23:01 1783 152113,902 15,118
A*24:02 1985 152713,190 14,810
A*24:03 754139511,895 689
A*25:01 1010 4204
A*26:01 4826
A*29:021634 35431090 301415964622
A*30:01 4679
A*31:01 3733
A*32:01 4744
A*33:01 1831 4431
A*33:03 5485
A*34:02 7463
A*36:01 2587 5234
A*43:01 661 3826
A*66:01 6275
A*66:02 6318
A*68:01 1980 5375555
A*68:02 823 2054 6196220
A*69:01 639 1557 5415
A*74:01 5083
A*80:01 537 2209 33551010
HLA-B ReactivityB*07:022638 5808 2593
B*08:01 1460
B*15:12 5171509 1304
B*15:162057 4253 3698
B*27:05 93216505912757
B*27:08 14591232
B*37:01808 1495 28491095
B*38:011073 1405 29231204
B*39:01 9171559
B*40:012573 4726 583549
B*40:02 841 71098217,10617,617
B*41:01 1288 114215,82717,864
B*42:01 180735327761469
B*44:02796 549 13732117
B*44:031888 1532 2212
B*46:01 613998
B*47:01 14473431
B*48:01 16123014
B*49:01 12482768
B*50:01 14881351
B*51:01 5892013
B*52:011606 3103
B*53:01 6111740 1235
B*54:01 7601909 1375
B*55:01 5521666 1493
B*56:01 12601578
B*57:012252 4064 503
B*59:012527 5685 2546
B*67:01119810152872 17,24817,353
HLA-CC*03:03 611
C*15:021283 16301300
C*17:011048 1365 2695997
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Ravindranath, M.H.; Ravindranath, N.M.; El Hilali, F.; Selvan, S.R.; Filippone, E.J. Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients. Antibodies 2022, 11, 18. https://doi.org/10.3390/antib11010018

AMA Style

Ravindranath MH, Ravindranath NM, El Hilali F, Selvan SR, Filippone EJ. Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients. Antibodies. 2022; 11(1):18. https://doi.org/10.3390/antib11010018

Chicago/Turabian Style

Ravindranath, Mepur H., Narendranath M. Ravindranath, Fatiha El Hilali, Senthamil R. Selvan, and Edward J. Filippone. 2022. "Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients" Antibodies 11, no. 1: 18. https://doi.org/10.3390/antib11010018

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop